 
Effect of COMT  Genetic Polymorphisms on Response to 
Propranolol Therapy in Temporomandibular Disorder  
 
 
NCT number :  02437383  
Document Date :  12 February 2018  
 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
i Effect of COMT  Genetic P olymorphisms on Response to 
Propranolol Therapy in Temporomandibular Disorder  
NIDCR Protocol Number:  14-067-E 
 
NIDCR Funding Mechanism: DE024169- 01 
 
Principal Investigator:  Inna Tchivileva , MD  
NIDCR Program Official : Gallya Gannot, DMD, PhD 
 
Version Number: 12.0 
12 Feb 2018  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
ii STATEMENT OF COMPLIA NCE  
The study will be carried out in accordance with Good Clinical Practice (GCP) as required by the 
following: 
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies 
(45 CFR Part  46, 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 312 ) 
• International Conference on Harmonisation  (ICH) E6 
• National Institutes of H ealth  (NIH) Clinical Terms of Award  
All key personnel have completed Human Subjects Protection Training.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
iii SIGNATURE PAGE : UNIVERSITY OF NORTH CAROLINA  
The signature below constitutes the approval of this protocol and the attachments  and provides 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable US federal regulations and ICH guidelines.  The protocol 
should be signed by the clinical site investigator who is responsible for the day -to-day study 
implementation at his/her specific clinical site.  
Site Investigator:  
 
Signed:   Date:   
 Inna Tchivileva, MD  
Research Assistant Professor  
University of North Carolina School of Dentistry    
 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
iv SIGNATURE PAGE : UNIVERSITY  OF FLORIDA  
The signature below constitutes the approval of this protocol and the attachments  and provides 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable US federal regulations and ICH guidelines. The protocol should be signed by  the clinical site investigator who is responsible for the day -to-day study 
implementation at his/her specific clinical site.  
Site Investigator:  
 
Signed:   Date:   
 Roger Fillingim, PhD  
Professor  
University of Florida College of Dentistry    
 
  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
v SIGNATURE PAGE: UNIVERSITY  AT BUFFALO  
The signature below constitutes the approval of this protocol and the attachments  and provides 
the necessary assurances that this trial will be conducted according to all stipulations of the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable US federal regulations and ICH guidelines. The protocol should be signed by the clinical site investigator who is responsible for the day -to-day study 
implementation at his/her specific clinical site.  
Site Investigator:  
 
Signed:   Date:   
 Richard Ohrbach , DDS, PhD 
Associate Professor  
University at Buffalo School of Dental Medicine    
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
vi TABLE OF CONTENTS  
 Page  
Statement of Compliance ............................................................................................................ ii 
Signature Page: University of North Carolina  ............................................................................. iii 
Signature Page: University of Florida  ......................................................................................... iv 
Signature Page: University at Buffalo  .......................................................................................... v 
Table of Contents  ....................................................................................................................... vi 
List of Abbr eviations  .................................................................................................................... x 
Protocol Summary  .................................................................................................................... xii 
1 Key Roles  ......................................................................................................................... 17 
2 Introduction: Background Information and Scientific Rationale ......................................... 21 
2.1 Background Information  ........................................................................................ 21 
2.1.1  Background on Temporomandibular Disorder  ........................................... 21 
2.1.2  Current Pharmacologic Management of TMD  ............................................ 21 
2.1.3  Adrenergic System in Pathophysiology of TMD  ......................................... 21 
2.1.4  Background on Propranolol  ....................................................................... 22 
2.1.5  Background on Catechol -O-Methyltransferase as a Genetic Marker of 
Response to Propranolol ........................................................................... 22 
2.2 Rationale .............................................................................................................. 23  
2.3 Potential Risks and Benefits  ................................................................................. 24 
2.3.1  Potential Risks  .......................................................................................... 24 
2.3.2  Known Potential Benefits ........................................................................... 25 
2.4 Study Objectives  ................................................................................................... 25 
2.4.1  Primary Objective  ...................................................................................... 25 
2.4.2  Secondary Objectives  ............................................................................... 25 
2.4.3  Exploratory Objectives  .............................................................................. 26 
2.5 Study Outcome Measures  .................................................................................... 26 
2.5.1  Primary Outcome Measures  ...................................................................... 26 
2.5.2  Secondary Outcome Measures  ................................................................. 26 
3 Study Design Overview  ................................................................. ................................... 27 
4 Study Enrollment and Withdrawal  ..................................................................................... 28 
4.1 Participant Inclusion Criteria ................................................................................. 28 
4.2 Participant Exclusion Criteria ................................................................................ 29 
4.3 Strategies for Recruitment and Retention ............................................................. 30 
4.4 Treatment Assignment Procedures  ....................................................................... 31 
4.4.1  Randomization Procedures  ....................................................................... 31 
4.4.2  Blinding Procedures  .................................................................................. 31 
4.4.3  Unblinding Procedures  .............................................................................. 31 
4.4.4  Reasons for Participant Withdrawal ........................................................... 32 
4.4.5  Handling of Withdrawals and Discontinuation  ............................................ 32 
4.4.6  Suspension or Termination of the Study  .................................................... 33 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
vii 5 Study investigational Product and Placebo  ....................................................................... 33 
5.1 Investigational Product  .......................................................................................... 33 
5.1.1  Acquisition  ................................................................................................. 33 
5.1.2  Form ulation, Packaging, and Labeling....................................................... 33 
5.1.3  Product Storage and Stability  .................................................................... 34 
5.2 Dosage and Administration of Investigational Product  .......................................... 34 
5.3 Modification of Dosage of Investigational Product  ................................................. 34 
5.4 Placebo.................................................................................................................  34 
5.5 Accountability Procedures  .................................................................................... 35 
5.6 Assessment of Participant Compliance ................................................................. 35 
5.7 Concomitant Medications and Therapies  .............................................................. 35 
5.7.1  Rescue Medication  .................................................................................... 35 
5.7.2  Nonpharmacological Therapy  .................................................................... 36 
5.8 Protocol Deviations Related to the Use of Investigational Product and 
Concomitant Therapies  ......................................................................................... 36 
6 Study Schedule ................................................................................................................ 36 
6.1 Prescreening (Day -49 to Day -7) .......................................................................... 37 
6.2 Screening and Baseline Visit 0 (Day - 21 to Day -7) ............................................... 37 
6.3 Treatment (Visits 1- 4) ........................................................................................... 38 
6.3.1  Randomization and Titration Visit 1 (Day 0)  .............................................. 38 
6.3.2  Maintenance Visit 2 (Day 7 [+ 3 days])  ...................................................... 39 
6.3.3  Maintenance Visit 3 (Day 35 [± 7 days])  .................................................... 39 
6.3.4  Tapering Visit 4 (Day 63 [+6 days])  ........................................................... 40 
6.4 Follow -up Visit 5 (Day 77 [+ 7 days]) .....................................................................  41 
6.5 Early Termination Visit  ..........................................................................................  41 
6.6 Unscheduled Visit  ................................................................................................. 41 
7 Study Procedures  ............................................................................................................. 42 
7.1 Clin
ical Evaluations  ............................................................................................... 42 
7.1.1  Medical History  ..........................................................................................  42 
7.1.2  Vital Signs and Physical Measurements  .................................................... 42 
7.1.3  Pregnancy Test  ......................................................................................... 42 
7.1.4  Blood Draw  ............................................................................................... 42 
7.1.5  Electrocardiogram  ..................................................................................... 42 
7.1.6  Temporomandibular Disorder Examination ............................................... 43 
7.1.7  Tests for Heat Sensitivity  ........................................................................... 43 
7.1.8  Pressure Pain Threshold Measurements  ................................................... 43 
7.1.9  Manual Tender Point Examination  ............................................................. 43 
7.1.10  Daily Symptom Diary  ................................................................................. 44 
7.1.11  The Alcohol Use Disorders Identification Test  ........................................... 45 
7.1.12  Smoking Questionnaire  ............................................................................. 45 
7.1.13  Symptom Inventory  ................................................................................... 45 
7.1.14  Outcome Measure Questionnaires  ............................................................ 45 
7.2 Laboratory Evaluations  ......................................................................................... 47 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
viii 7.2.1  Clinical Laboratory Evaluations  ................................................................. 47 
7.2.2  Research Laboratory Evaluations  .............................................................. 47 
7.2.3  Specimen Preparation, Handling, and Shipping ........................................ 47 
8 Assessment of Safety  ....................................................................................................... 47 
8.1 Specification of Safety Parameters  ....................................................................... 47 
8.1.1  Unanticipated Problems  ............................................................................ 48 
8.1.2  Adverse Events  ......................................................................................... 48 
8.1.3  Serious Adverse Events  ............................................................................ 49 
8.2 Time Period and Frequency for Event Assessment and Follow -Up ....................... 49 
8.3 Characteristics of Adverse Events  ........................................................................ 49 
8.3.1  Relationship to Study Drug ........................................................................ 49 
8.3.2  Relationship to Study Procedures  ............................................................. 50 
8.3.3  Expectedness of AEs  ................................................................................ 50 
8.3.4  Severity of Event  ....................................................................................... 50 
8.4 Reporting Procedures  ........................................................................................... 50 
8.4.1  Adverse Event Reporting to IRB and NIDCR  ............................................. 50 
8.4.2  Unanticipated Problem Reporting to IRB and NIDCR  ................................ 51 
8.4.3  Serious Adverse Event Reporting to NIDCR .............................................. 51 
8.4.4  Reporting Abnormal Clinical Findings  ........................................................ 52 
8.4.5  Reporting of Pregnancy  ............................................................................. 52 
8.5 Halting Rules  ........................................................................................................ 53 
9 Study Ov ersight  ................................................................................................................ 53 
10 Clinical Monitoring  ............................................................................................................ 53 
11 Statistical Considerations  ................................................................................................. 54 
11.1  Study Hypotheses  ................................................................................................. 54 
11.1.1  Primary Hypothesis  ................................................................................... 54 
11.1.2  Secondary Hypothesis  .............................................................................. 54 
11.1.
3 Exploratory Hypotheses  ............................................................................ 55 
11.2  Sample Size Considerations  ................................................................................. 55 
11.3  Analysis Samples  ................................................................................................. 56 
11.3.1  Intention- To-Treat Sample ......................................................................... 56 
11.3.2  Per-Protocol Sample ................................................................................. 56 
11.3.3  Safety Sample  ........................................................................................... 56 
11.4  Analyses  ............................................................................................................... 56 
11.4.1  Analysis of the Primary Hypothesis  ........................................................... 56 
11.4.2  Analysis of the Secondary Hypotheses  ..................................................... 57 
11.4.3  Analysis of the Exploratory Hypotheses  .................................................... 58 
11.5  Planned Interim Analyses  ..................................................................................... 58 
12 Source Documents and Access to Source Data and Documents  ..................................... 59 
13 Quality  Control and Quality Assurance  ............................................................................. 59 
14 Protection of Human Participants  ..................................................................................... 60 
14.1  Institutional Review Board .................................................................................... 60 
14.2  Informed Consent Process  ................................................................................... 60 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
ix 14.3  Exclusion of Special Populations  .......................................................................... 60 
14.4  Participant Confidentiality  ..................................................................................... 60 
14.5  Future Use of Stored Specimens  .......................................................................... 61 
14.6  Data Handling and Record Keeping ...................................................................... 61 
14.7  Data Management Responsibilities  ....................................................................... 61 
14.8  Data Capture Methods  .......................................................................................... 62 
14.9  Types of Data  ....................................................................................................... 62 
14.10  Timing of Reports  ................................................................................................. 62 
14.11  Study Records Retention  ...................................................................................... 62 
14.12  Protocol Deviations  ............................................................................................... 62 
15 Publication/Data sharing Policy  ........................................................................................ 63 
16 Literature References  ....................................................................................................... 64 
Appendix A: Schedule of Events  ............................................................................................... 68 
Appendix B: Package Insert for Propranolol Hydrochloride extended- release ........................... 71 
 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
x LIST OF ABBREVIATION S 
ACR  American College of Rheumatology  
ADRB2  Adrenergic receptor β2 
ADRB3  Adrenergic receptor β3 
AE Adverse event 
APS Average pain sensitive  
AUDIT  Alcohol Use Disorders Identification Test  
CFR Code of Federal Regulations  
CMP  Clinical Monitoring Plan  
COMT  Catechol -O-methyltransferase  
CROMS  Clinical Research Operations and Management Support   
CSQ -R Coping Strategies Questionnaire Revised  
DCC  Data coordinating center  
DC/TMD  Diagnostic Criteria for Temporomandibular Disorder  
DNA  Deoxyribonucleic acid  
DSMB  Data and Safety Monitoring Board  
ECG  Electrocardiogram  
EDC  Electronic data capture  
FDA Food and Drug Administration  
FDAAA  Food and Drug Administration Amendments Act of 2007  
GCP  Good Clinical Practice  
GCPS  Graded Chronic Pain Scale  
GWAS  Genome -Wide Association Studies  
HIT-6 Headache Impact Test  
HPS High pain sensitive  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
IND Investigational New Drug (Application)  
IRB Institutional Review Board  
LPS Low pain sensitive  
MOP  Manual of Procedures  
NIDCR  National Institute of Dental and Craniofacial Research  
NIH National Institutes of Health  
NRS  Numeric rating scale  
NSAID  Nonsteroidal anti -inflammatory drug  
OCTOM  Office of Clinical Trials and Operations Management  
OHRP  Office of Human Research  Protection  
PGIC  Patient Global Impression of Change  
PI Principal Investigator  
PPT Pressure pain threshold  
SAE Serious adverse event 
SCL-90R Symptom Checklist 90 -Revised  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
xi SF-12 v2 Short Form 12 Health Survey  Version 2  
TENS  Transcutaneous electrical nerve stimulation  
TMD  Temporo mandibular d isorder  
TMJ Temporomandibular joint  
UB University at Buffalo  
UF University of Florida  
UNC  University of North Carolina  
UP Unanticipated problem  
US United States  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
xii PROTOCOL SUMMARY  
Title:  Effect of COMT  Genetic Polymorphisms on Response to 
Propranolol Therapy in Temporomandibular Disorder  
Short Title:  Study of Orofacial Pain and PropRANOlol (SOPPRANO)  
Précis: 
 
 
 A total of 200 participants of either sex  and any race or ethnicity , 
recruited at  3 clinical sites,  aged 18 to 65 years with chronic 
temporomandibular disorder (TMD) , will be randomized in a 1:1 
ratio to propranolol or placebo in a parallel -group, blind ed clinical 
trial. Participant s will attend 6 clinic visits over a period of 12 to 
15 weeks.   
Potential participant s will be prescreened by telephone or at a 
clinic visit. During the Screening and B aseline Visit, participant s 
will be consented, evaluated for eligibility, and assessed for 
baseline characteristics . Baseline procedures will include clinical 
tests and examinations  and the administration of questionnaires . 
Additional questionnaires will be distributed to be completed and returned at the following visit.   
At the R andomization and Titration V isit, participant s will be 
randomized to  propranolol or placebo and will begin a 10- week 
drug treatment phase that is divided into 1 week of drug titration , 
8 weeks of drug maintenance, and 1 week of drug tapering. During treatment , many of the baseline assessments will be 
repeated. T he final study visit will occur 1 week after drug 
tapering  ends . 
The primary endpoint will be a weekly pain index derived from a 
daily symptom diary. S econdary endpoints will be additional 
ratings of clinical pain ; examiner  assessments of experimental 
pain sensitivity ; participant  ratings of physical function, emotional 
function, and global improvement ; occurrence of symptoms and 
adverse events  (AEs) ; and use of rescue medications . DNA 
analyses  will be conducted to identify polymorphisms in the gene 
that encodes catechol -O-methyltransferase ( COMT ), an enzyme 
that metabolizes catecholamines such as epinephrine, norepinephrine, and dopamine, and is associated with responses 
to pain. 
Objectives:  
 The primary objective is to investigate  the efficacy of extended-
release propranolol compared with  placebo in the reduction of a 
pain index in participant s with TMD  at week 9 of treatment (at 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
xiii Visit 4) . 
The secondary objectives are  as follows:  
• To investigate gene- by-treatment  group interaction to 
determine whether the e fficacy of extended -release 
propranolol in the reduction of the pain index varies  
according to participant s' polymorphisms in the coding region 
of the COMT  gene.  
• To investigate the efficacy of extended- release propranolol 
compared with placebo using secondary endpoints . 
The exploratory objectives are as follows:  
• To investigate whether the efficacy of extended -release 
propranolol in the reduction of the pain index varies 
according to participants' polymorphisms in 3 other genetic 
regions.  
• To investigate whether the efficacy of extended -release 
propranolol in the reduction of the pain index varies according to various phenotypic characteristics. 
• To collect and archive biospecimens for future biological and 
statistical analyses . 
Population:  200 participants of either sex and any race or ethnicity  between 
18 and 65  years of age (inclusive) with chronic TMD  will be 
randomized 
Phase:  Phase II  
Number of Sites:  Three clinic al sites:  
• University of North Carolina School of Dentistry  at Chapel 
Hill, NC  
• University of Florida College of Dentistry , Gainesville, FL 
• University at Buffalo School of Dental Medicine, Buffalo, NY  
Study Duration:  Approxi mately 3 years  
Participant Duration: 12 to 15 weeks  
Description of Agent:  Propranolol hydrochloride extended- release in 60 mg capsules 
taken orally  twice a day  over a 10- week treatment period 
Enrollment  Duration: Approximately 2 years  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
xiv Figure 1:  Schematic of Study Design  
 
 
Screening  
 Baseline  
V0 
Prescreening  
Randomization  
Drug Titration  
V1 
0 
Maintenance  
V2 
1 
Maintenance  
V3 
5 
Taper  
V4 
9 
Last Visit  
V5 
11 
0 to 4 
Weeks 
Week  
Visit 
Propranolol  
Placebo  
-3 to -1 
 -7 to -1 
Treatment Ends  
10 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
xv  
Prescreening  
Day -49 to Day -7 
  
 
Visit 0:  
Screening  
and Baseline  
Day -21 to Day -7 
 
 
 
  
Visit 1  
Day 0   
 
  
 
  
 
  
 
 
 
 
Visit 2  
Day 7 - 10 
 
   
 
Visit 3  
Day 35 ± 7  
 
 
 
 
Visit 4  
Day 63 +6  
  
 Screen and baseline approximately 300 participants for  study inclusion.  Obtain 
informed consent. Screen potential subjects by  inclusion and exclusion criteria; 
obtain history  and Symptom Inventory, document.  Perform baseline assessments 
(tender point and TMD exams, heat and pressure tests, 12- lead ECG) and ur ine 
pregnancy test (females). Dispense outcome measure questionnaires and daily 
symptom diaries .  
Obtain history and Symptom Inventory, document. Collect and assess daily 
symptom diaries. Assess AEs. Perform blood draw for DNA analyses , optional 
blood draw for future analyses , and urine pregnancy test (females). Review 
eligibility; collect outcome measure questionnaires.    
Obtain history and Symptom Inventory, document. Collect and assess daily 
symptom diaries and drug containers. Assess AEs. Perform optional blood draw 
for future analyses, urine pregnancy test (females), TMD exam, and heat and 
pressure tests.  Administer out come measure questionnaires. Dispense study 
drug.  Obtain history and Symptom Inventory, document. Collect and assess daily 
symptom diaries and drug containers. Assess AEs. Perform urine pregnancy test 
(females), TMD exam, and heat and pressure tests.  Administer outcome measure 
questionnaires. Dispense study drug.  
Arm 2  
100 subjects  
 Randomize and dispense study drug  
Arm 1  
100 subjects  
Obtain history and Symptom Inventory, document. Collect and assess daily 
symptom diaries and drug containers. Assess AEs. Perform urine pregnancy test 
(females).  Administer Pain Questionnaire. Dispense study drug.  Prescreen approximately 600 participants.  Obtain verbal consent. Complete 
prescreening interview. Pres creen potential subjects by  inclusion and exclusion 
criteria . Collect contact information.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
xvi  
 
 
  
 
Visit 5 
Day 77 + 7  
  
 
 
 
  
 
                          Final Assessments  
Obtain history and Symptom Inventory, document. 
Collect and assess daily symptom diaries and drug 
containers. Assess AEs. Perform urine pregnancy 
test (females).  Administer Pain Questionnaire.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
17 1 KEY ROLES  
Co-Principal Investigator s: Inna Tchivileva, MD  
Research Assistant Professor  
5417J Koury Oral Health Sciences  
School of Dentistry  
UNC Chapel Hill  
CB# 7455 
Chapel Hill, NC 27599 -7455 
Phone: (919) 537- 3291  
Fax: (919)  966-5339  
E-mail: chivilei@dentistry.unc.edu 
 Gary Slade, BDSc, Dip DPH, PhD 
Distinguished Professor  
5417B Koury Oral Health Sciences  
School of Dentistry  
UNC Chapel Hill  
CB# 7455 Chapel Hill, NC 27599 -7455 
Phone: (919) 537- 3273  
Fax: (919)  966-5339  
E-mail: gary_slade@dentistry.unc.edu  
 Roger Fillingim, PhD 
Professor  
College of Dentistry, University of Florida  
1329 SW 16th St reet 
PO Box 103628  
Gainesville, FL 32610- 3628 
Phone: (352) 273- 5963  
Fax: (352) 273- 5985  
E-mail: rfilling@ ufl.edu 
 
Richard Ohrbach, DDS, PhD  
Associate Professor  
University at Buffalo School of Dental Medicine  
355 Squire Hall  
Buffalo, NY 14214- 1412  
Phone: (716) 829- 3590  
Fax: (716) 829- 3554  
Email: ohrbach@buffalo.edu 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
18 NIDCR Medical Monitor:  Kevin McBryde, MD  
National Institute of Dental and Craniofacial Research/NIH  
6701 Democracy Blvd. Room 638 Bethesda, MD 20892 
Phone: (301) 594- 0170  
Fax: (301) 480- 8319  
Email: mcbrydekd@nidcr.nih.gov  
NIDCR Program Official:    Gallya Gannot, DMD,  PhD 
National Institute of Dental and Craniofacial Research/NIH  
6701 Democracy Boulevard, Room 632 
Bethesda, MD 20892- 4878 
Phone: (301) 451-5096  
E-mail: gallya.gannot@nih.gov  
Co-Investigators: Alan Hinderliter, MD  
Associate Professor  
6th floor, Burnett -Womack Bldg. , Division of Cardiology  
Campus Box 7075  
Chapel Hill, NC 27599 -7075  
Phone:  (919) 843- 5447  
Fax: (919) 966- 1743  
E-mail: alan_hinderliter@med.unc.edu  
 Pei Feng Lim, BDS, MS  
Clinical Ass ociate Professor  
5417G Koury Oral Health Sciences Building 
School of Dentistry  
UNC Chapel Hill  
CB# 7455 Chapel Hi ll, NC 27599 -7455 
Phone: (919) 265- 3023  
Fax: (919) 966- 2991  
E-mail: peifeng_lim@dentistry.unc.edu  
 Margarete Ribeiro- Dasilva, DDS, PhD
 
1395 Center Drive, D9- 22 
Gainesville, FL 32610 
Phone: (352) 273- 7954  
Fax: (352)  846-1643  
E-mail: mdasilva@dental.ufl.edu  
 
David Sheps , MD, MSPH  
2004 Mowry Road, Room 4234   
Gainesville, FL 32610- 3010 
Phone: (352) 294- 5947  
Fax: (352)  273-5365  
E-mail: dssheps@phhp.ufl.edu  
 
 
 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
19 John Campbell, DDS  
Associate Professor  
University at Buffalo School of Dental Medicine  
112 Squire Hall  
Buffalo, New York 14214  
Phone:  (716) 829- 2722  
Fax: (716) 829- 3019  
E-mail: jc294@buffalo.edu 
 
Thomas Cimato, MD, PhD   
Associate Professor  
875 Ellicott Street, Suite 7030                                            
Division of Cardiovascular Medicine  
Clinical and Translational Research Center  
Buffalo, New York 14203  
Phone:  (716) 829- 2663  
Fax: (716) 854- 1840  
E-mail: tcimato@buffalo.edu 
  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
20 Institutions:  The University of North Carolina at Chapel Hill  
School of Dentistry  
Manning Dr ive & Columbia St reet 
Campus Box 7450  
Chapel Hill, NC 27599 -7450 
 
The University of Florida  
College of Dentistry  
1600 SW  Archer R oad 
Gainesville FL 32610- 3003 
 
The University at Buffalo  
School of Dental Medicine 3435 Main St #32 
Buffalo, NY 14214- 1412  
 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
21 2 INTRODUCTION: BACKGROUND INFORMATI ON AND 
SCIENTIFIC RATIONALE 
2.1 Background Information  
2.1.1  Background on T emporomandibular Disorder  
The term “temporomandibular disorder ” (TMD)  encompasses  all musculoskeletal disorders of 
the masticatory system .1 Commo n TMDs include myalgia, arthralgia, temporomandibular joint 
(TMJ) disc displacements with and without reduction, and TMJ degenerative joint diseases . A 
recent study reported that the most prevalent TMD diagnostic group is muscle dysfunction.2 
TMD is among the most common chronic musculoskeletal pain conditions  and has significant 
societal cost s.3 The prevalence of TMD ranges from 6% to 12% in the general population.4 
Overall,  TMD  result s in 17.8 million  lost w ork days per year for every 100 million working adults 
in the US.5 Chronic TMD is associated with substantial disability and suffering , and it negatively 
impacts the quality of life .6 Jaw pain is the most common symptom that compels patients to 
seek treatment . One study reported  an average TMD pain intensity rating  of 4.3 on a 1 1-point 
scale, similar to the averages reported for chest pain and back pain.7 In addition to facial pain, 
TMD patients frequently report  various comorbid  idiopat hic pain conditions such as headaches, 
low back pain, and fibromyalgia.8, 9 Novel approaches to TMD therapy are urgently needed to 
improve clinical outcomes and reduce the economic impact of this debilitating disorder.  
2.1.2  Current Pharmacologic Management of TMD  
Although there is  currently no medicinal product labeled by the Food and Drug Administration 
(FDA) specifically for the management of TMD , several classes of drugs are used to attempt to 
relieve TMD -associated pain, such as nonsteroidal anti -inflammatory drugs  (NSAIDs) , 
corticosteroids, benzodiazepines, sedative hypnotics, muscle relaxants, opioids, 
antidepressants, and anticonvulsants. However, evidence clearly establishing efficacy and 
safety of these drugs in the management of TMD is scarce.10, 11 The justification for their use is 
often based on uncontrolled clinical reports claiming efficacy, poorly controlled clinical trials, or  
clinical trials in other  pain disorders (e.g.,  acute postsurg ical dental pain, arthritic pain, chronic 
lower back pain, and neuropathic pain ). There is a growing need for controlled clinical trials in  
the TMD population.  
2.1.3  Adrenergic System in P athophysiology of TMD  
The physiological mechanisms responsible for TMD sym ptoms are poorly understood. A 
growing body of evidence suggests that enhanced β -adrenergic drive contributes to the 
pathogenesis of TMD and other complex persistent pain conditions. For example, i ndividuals 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
22 with myofa scial pain conditions have elevated ca techolamine levels and augmented 
sympathetic responses to stressors.12, 13 Additionally, fibromyalgia patients have higher basal 
norepinephrine levels and exaggerated norepinephrine responses to the proinfl ammatory 
cytokine, interleukin -6.14 In animal models, epinephrine produces mechanical hyperalgesia and 
sensitized cultured dorsal root ganglion neurons via action at a β -adrenergic receptor.15 
While  increased β-adrenergic drive appears to heighten pain, β-adrenergic antagonists can 
reduce clinical pain and/or nociceptive sensitivity. A recent study of a single -dose infusion of 
propranolol in TMD and fibromyalgia patients revealed a short -term improvement in clinical pain 
ratings.16 The mixed β -adrenergic  receptor/5- hydroxytryp tamine ( HT)1A presynaptic receptor 
antagonist pindolol was similarly efficacious in alleviating the cardinal symptoms of fibromyalgia, 
namely pain, stiffness, and nonrestful sleep.17 In a rodent model of TMD, both the nonselective 
β-adrenergic receptor antagonist propranolol and a selective β2-blocker  impaired pain 
behavior.18 In addition, the intramuscular injection of low -dose propranolol in rats reduced 
inflammatory pain associated with carrageenan- induced inflammation of the gastrocnemius 
muscle.16 
2.1.4  Background on P ropranolol  
The study hypothesis is that low -dose therapy with the nonselective β -adrenergic receptor 
antagonist propranolol will provide an efficacious and safe treatment for painful TMD. 
Extended- release propranolol is approved for the treatment of hypertension, angina pectoris 
due to coronary atherosclerosis, migraine, and hypertrophic  subaortic stenosis.19 It has 
well-studied pharmacodynamic and pharmacokinetic characteristics and side- effect profile. 
Peak blood level  following dosing with an extended- release formulation of propranolol 
hydrochloride occurs at approximately 6 hours, and the apparent plasma half -life is 
approximately 10 hours. Data from our preliminary study suggest that low -dose short -acting 
propranolol produces minimal side effects (e.g., mild nausea, diarrhea, and fatigue occurred at 
similar rates during propranolol and placebo treatment).20  
2.1.5  Background on C atechol -O-M ethyltransferase as a Genetic Marker 
of Response to Propranolol  
Abnormalities in catecholamine physiology are associated with diminished activity of catechol -O-methyltransferase ( COMT ), a ubiquitously expressed enzyme that metabolizes 
catecholamines such as epinephrine, norepinephrine, and dopamine.
21 TMD  patients exhibit ed 
lower COMT  activity rela tive to pain- free controls.22 Our group and others have shown that 
various functional polymorphisms in the COMT  gene that  result in 3 - to 15- fold reductions in 
COMT  activity23, 24 are associated with fibromyalgia ,25 migraine,26 experimental pain 
sensitivity,27, 28 and increased morphine efficacy in cancer pain t reatment.29 
Three major haplotypes of COMT , designated as low pain sensitive (LPS), average pain 
sensitive (APS), and high pain sensitive (HPS), accounted for 11% of variability in experimental 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
23 pain sensitivity in women.27, 30 The LPS haplotype produces higher levels of COMT  enzymatic 
activity than the APS or HPS haplotypes.31 In our recent prospective cohort study, the presence 
of even a single LPS haplotype was found to diminish the risk of developing TMD  as much as 
2.3-fold.27 To identify the receptor mechanism whereby elevated catecholamine levels resulting 
from reduced COMT  activity modulate pain sensitivity, our group conducted a set of behavioral 
pharmacologic studies in rats receiving a COMT  inhibitor. We found  that COMT  inhibition 
enhanced mechanical and thermal pain sensitivity  comparable to that produced by 
carrageenan, a chemical well known for its ability to sensitize nociceptors and increase pain 
behavior. COMT -related mechanical and thermal hyperalgesia was blocked by propranolol  or by 
combined administration of selective β 2- and β3-adrenergic receptor  antagonists  but not by 
dopaminergic, α- , or β 1-adrenergic antagonists , suggesting that the hyperalgesia is selectively 
mediated by  a β2/3-adrenergic mechanism .32 
We hypothesize that individuals with lower COMT  activity , such as those not carrying the LPS 
haplotype, will experience relatively greater reduction in TMD pain from propranolol therapy 
than individuals with other COMT  haplotypes  that confer greater COMT  activity . Genotyping of 
the COMT  gene will allow us to evaluate this hypothesized gene -by-treatment  group interaction, 
potentially identifying a subset of TMD patients most likely to benefit from propranolol treatment.  
2.2 Rationale  
A randomized, double– blind, placebo- controlled, crossover pilot study  with a 1-week treatment  
with propranolol  (20 mg twice a day) has been compl eted in patients with painful TMD .20 In this 
study, the number of patients reporting a reduction in pain intensity rating was greater during 
propranolol treatment (p = 0.014) compared with placebo. Propranolol also significantly reduced 
the composite pain index (p  = 0.02) , but did not decrease other clinical and experimental pain 
ratings. When stratified by the COMT high-activity  haplotype (LPS) , a beneficial effect of 
propranolol on pain perception was noted in participants  not carrying this haplotype, a 
diminished benefit was observed in the heterozygotes, and no benef it was noted in the LPS 
homozygotes ; this effect was statistically significant in many pain measures.  In the present trial , 
the duration of therapy for TMD with propranolol will be extended to 10 weeks, an extended- release instead of short -acting formula of the drug will be administered to enhance 
patient compliance over a longer treatment period, and the propranolol extended- release dose 
will be increased to 60 mg twice a day. Additionally, a parallel instead of crossover design will 
be utilize d to reduce the drop- out rate and avert potential carryover effect s. 
Consensus recommendations for clinical trials of pain from the IMMPACT group
33 encourage 
investigators to evaluate five outcomes related to pain: (1) pain; (2) physical functioning; (3) emotional functioning; (4) participant global ratings of impr ovement; and (5) symptoms and 
adverse events  (AEs) . They also encourage investigators to collect data to permit reporting of 
study conduct consistent with the recommendations of the CONSORT group.
34 Accordingly, this 
protocol proposes endpoints and data recording that will address the requirements of both sets 
of recommendations.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
24 2.3 Potential Risks and Benefits  
2.3.1  Potential Risks  
Investi gational Drug.  The investigational product is propranolol hydrochloride 
extended- release capsules . Propr anolol has been available commercially for over 40 years  and 
is routinely used to treat  hypertension, migraine, and essential tremor at doses much greater 
than will be  administered in this study. As propranolol is FDA approved for many disorders and 
has well-characterized pharmacological and side effects profile s, the risk s for TMD patients 
using this drug  at the proposed dose are low. 
The package insert for p ropranolol hydrochloride extended- release capsules  is shown in 
Appendix B . Propranolol is contraindicated in patients with cardiogenic shock, sinus bradycardia 
and greater than a first degree block, bronchial asthma, and known hypersensitivity to  
propranolol hydrochloride. Additionally, propranolol is not recommended for use in patients with 
cardiac failure, nonallergic bron chospasm, major surgery, diabetes, thyrotoxicosis, or Wolff -
Parkinson- White syndrome. Patients with the above- listed conditions will not be included in the 
study. At al l clinic visits  after Pre screening , resting blood pressure and heart rate will be 
monitored.  A 12-lead electrocardiogram ( ECG ) will be performed at the Scree ning and B aseline 
Visit. The ECG will be reviewed by a cardiologist who will determine the clinical  significance of 
any ECG abnormalities . Participants will be asked to report any planned surgical procedures to 
the study principal investigators ( PIs) since p ropranolol  hydrochloride extended- release may 
increase the risks associated with general anesthesia and surgical procedures.  
In a study in w hich male and fe male rats were exposed to propranolol hydrochloride in their 
diets, from  60 days prior to mating  and throughout pregnancy  and lactation  for two generations,  
there were no effects on fertility. Contraception in males will not be required in this study. 
However, there are no adequate and well- controlled studies of propranolol in pregnant women.   
Pregnancy is an exclusion criterion  and a participant  discontinuation criterion in this study. A 
pregnancy test will be conducted on all women of childbearing potential  at all visits . In addition, 
propranolol is excreted in human milk; therefore , nursing is an exclusion criterion for this study.   
Cardiovascular, central nervous system, gastrointestinal, allergic, respiratory, hematologic, 
autoimmune, skin and mucous membranes, and genitourinary AEs  have been observed in 
patients using propranolol.  All reportable AEs will be collected from the Screening and Ba seline 
Visit through the last clinic visit.  
Electrocardiogram.  Electrode stickers  placed on the participant ’s skin  may cause discomfort  
when removed. Trained personnel will conduct the procedure. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
25 Questionnaires.  A participant may experience discomfort  associated with being asked personal 
questions about her  or his health history, symptoms, or emotional feelings.  Participant s will be 
told that they may choose not to answer any questions that cause discomfort.  
TMD Examination and Psychophysical Tests.  Four assessments of this kind will be 
performed: the TMD examination ( Section  7.1.6 ), tests for heat sensitivity (Section 7.1.7 ), tests 
for pressure pain threshold (PPT) (Section  7.1.8 ), and a manual tender point examination 
(Section 7.1.9 ). Assessmen ts of muscle and TMJ sensitivity to digital palpation during the TMD 
examination, responses  to masticatory muscle pressure threshold tests, and responses to 
painful heat stimuli are designed to evoke brief pain or discomfort during application of the 
stimulus; however, none of these assessments are expected to result in lasting discomfort or 
damage to affected tissues. Transient  redness or tenderness of skin is possible after tests.  All 
testing modalities will be conducted within a range of stimulus intensities that produce a level of 
pain or discomfort  that is acceptable to the participant . No test will exceed this range , and all 
tests will end upon completion of the modality or upon the participant ’s request, whichever 
comes first.  
Blood Collection.  There is a possibility of mild pain  and bruising associated with a blood draw.  
Trained personnel  will perform the  blood collection  using standard procedures . 
Violation of C onfidentiality.  The risk of violation of confidentiality  exists because human 
participant s are providing personal information, including genetic data. Procedures to minimize 
risks to confidentiality are described in Section 14.4 . 
2.3.2  Known Potential Benefi ts 
Participant s may or may not benefit from receiving the investig ational drug by experiencing 
decreased pain and improved functionality.  In the absence of any approved TMD medication, 
this search for an efficacious, safe, and affordable treatment may benefit many TMD patients  in 
the future. In addition, the proposed clinical trial will advance our knowledge of the role of the 
adrenergic system in the pathogenesis of TMD.  
2.4 Study Objectives  
2.4.1  Primary Objective  
The primary objective is to investigate  the efficacy of extended- release  propranolol compared 
with placebo in the reduction of a pain index (defined in S ection  2.5.1 ) in participants with TMD 
at week 9 of treatment (at Visit 4) . 
2.4.2  Secondary Objectives 
The secondary objectiv es are as follows:   
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
26 • To investigate gene- by-treatment  group interaction to determine whether the efficacy of 
extended- release propranolol in the reduction of the pain index var ies according to 
participant s' polymorphisms in the coding region of the COMT  gene. 
• To investigate the efficacy of extended- release propranolol compared with  placebo using 
secondary endpoints, namely: (1)  additional pain ratings; (2) examiner assessments of 
experimental pain sensitivity; (3)  participant ratings of physical function, emotional 
function, and global impression of change; (4)  occurrence of symptoms and AEs; and 
(5) use of rescue medications.  
2.4.3  Exploratory Objectives  
The exploratory objectives are  as follows : 
• To investigate whether the efficacy of extended -release propranolol in the reduction of 
the pain index varies according to participant s' polymorphisms including, but not limited 
to three other  genetic regions: 1) the COMT  promoter area; 2) adrenergic receptor β2 
(ADRB2)  gene; and 3) the adrenergic receptor β3 (ADRB3)  gene . 
• To investigate whether the efficacy of extended -release propranolol in the reduction of 
the pain index varies according to various phenotypic characteristics.   
• To collect and archive biospecimens for future biological and statistical analyses . 
2.5 Study Outcome Measures  
2.5.1  Primary Outcome Measures  
The primary endpoint will be a weekly mean pain index , representing the arithmetic mean  of 
daily pain index values  during the week prior to the study visit. The pain index will be computed 
during analysis as the  product of the pain intensity  score , reported on a 0- 100 numeric rating 
scale (NRS) , multiplied by the pain duration score , reported on a 0 -100 percentage scale,  each  
as reported in the D aily Symptom  Diary. The weekly mean pain index will be computed for the 
week prior to randomization and for each week during the treatment phase.  The weekly mean 
pain index will be calculated if a participant completes  at least 4 of the 7 daily reports of pain 
intensity and duration during the 7 -day period prior to the visit. When there are fewer than 
4 daily reports , the weekly mean pain index  will be considered  missing . 
2.5.2  Secondary Outcome Measures 
DNA analyses of blood samples will be conducted to identify polymorphisms in the gene that 
encodes catechol -O-methyltransferase (COMT) . Assessments of pain intensity (NRS 0- 100) 
and pain duration (0- 100 percentage scale) from the Daily Symptom Diary will be used as 
secondary outcomes. Additional assessments of clinical pain,  heat and pressure pain,  jaw 
function, health status, emotional st atus, participant  ratings of global improvement,  sleep, 
somatic symptoms , AEs , and the use of rescue medication will be made  by questionnaires and 
examinations, as described in Section 7.1. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
27 3 STUDY DESIGN  OVERVIEW  
Two hundred participants  with chronic TMD  recruited at 3 clinic al sites, will be randomized in a 
1:1 ratio to propranolol or placebo in a parallel -group, blind ed clinical trial. Participants will be 
limited to age 18 – 65 years because pharmacokinetic data are not available for patients over 
65 years for extended -release propranolol hydrochloride; s tandard prop ranolol  drug clearance is 
decreased and half -life increased in older populations . Additionally , with aging, arthralgia, 
osteoarthritis, and osteoarthrosis  become more pr evalent TMD diagnoses than myalgia; 
propranolol will not  be effective for these types of TMD.35  
Participant s will attend 6  clinic visits over a  period of 12 to 1 5 weeks ( Figure 1). The study 
should be completed in 3 years, with participant  recruitment occurring  during years 1 and 2.  
Prescreening will be performed either in the clinic or over the telephone, and poten tially eligible 
participant s will be scheduled for a Screening and B aseline V isit (Visit 0) . During Visit 0, 
participant s will be consented and evaluated for eligibility , and information including 
demographics, medical history, and concomitant medications will be collected. Additionally,  
participant s will be assessed for pain, health status,  jaw function, emotional functioning, sleep, 
and somatic symptoms, among other measures . Procedures will include  clinical examinations  
and tests and the dispensation of various questionnaires , all of which are listed in the Schedule 
of Events ( Appendix A ). 
At Visit 1 , participant s who show compliance with the Daily Symptom Diary (at least 4 daily 
entries  within 7 days) and meet the pain score  and all other eligibility requirements will be 
randomized to propranolol or placebo and wil l begin a 10- week drug treatment phase that is 
divided into 1 week of drug titration , 8 weeks of drug maintenance, and 1 week of drug tapering. 
During that period, Visits 2-4 will take place, and many of the baseline assessments will be 
repeated.  The final study visit, Visit 5, will occur 1 week after drug tapering ends and 2 weeks 
after Visit 4. 
The primary endpoint will be the weekly  pain index derived from the D aily Symptom D iary. 
Efficacy will be evaluated as the difference between the propranolol and placebo arms  in the 
mean change in the pain index during treatment. In addition, variation in efficacy will be 
compared between groups of participant s classified according to polymorphism s in the coding 
region of the COMT  gene .  
Enrollment will not be stratified accor ding to COMT  genotype because  in the pilot study sample, 
the haplotype variants were sufficiently distrib uted for statistical  evaluation of a treatment -
haplotype interaction without stratified randomization. In the pilot study, 30% of participant s had 
no copies of the LPS haplotype, 50% had one copy, and 20% had two copies.  Stratification by  
COMT  genotype would significantly increase the complexity of enrollment  and could delay the 
start of treatment for participant s while their DNA  test results were pending. The DNA analyses 
will be conducted after all participant s have been enrolled.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
28 4 STUDY ENROLLMENT AND  WITHDRAWAL  
4.1 Participant  Inclusion Criteria  
A participant  must meet all of the following inclusion criteria to be eligible for initial enrollment 
and randomization: 
1) Provides  a signed and dated informed consent form  
2) Is between 18 and 65  years of age (inclusive ; male or female and any race or ethnicity)  
3) Meets  diagnostic criteria  for TMD, Group I I: Masticatory Muscle Disorders , 1A: 
Myalgia36 
4) Has experienced f acial pain for at least 3 months  
5) Has experienced f acial pain for at least 10 days of the last 30 days  
6) At Screening and Baseline Visit (Visit 0), reports  an average pain intensity rating  over 
the past week of ≥  30 on a numerical rating scale (0- 100) 
7) At randomization (Visit 1 ), has satisfactorily completed at least 4 entries per week in the 
Daily Symptom Diary within the preceding week and reported  an average pain intensity 
score ≥  30 on a numerical rating scale (0 -100) or reports a rating of average daily pain 
intensity of ≥30 on the same scale on at least 3 days over the past week  
8) If taking a prescription medication (with the exception of prescription formulations of 
NSAIDs, acetaminophen, and aspirin) episodically  (or as needed)  for the management 
of pain, agrees to discontinue its use prior to or at the  Screening and  Baseline Visit 
9) If taking a prescription medication daily for the management of  pain, agrees  to continue 
the daily use of the  medication throughout the study  
10) If taking an over -the-counter pain medication daily, agrees to continue the daily use of 
the medication throughout  the study  
11) Agrees to not commence any new prescription medication for the management of pain 
throughout the study  
12) Agrees to not commence  any injection therapy  for pain (e.g., tender or trigger point 
injections, steroid injections) during the course of the study  
13) Agrees to not use acupuncture, biofeedback, or transcutaneous electrical nerve 
stimulation (TENS) for the management of pain during the course of the study  
14) Agree s to not commence occlusal splint  therapy during the course of the study  
15) Agrees to continue use of splint therapy if commenced more than 30 days previously  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
29 16) Females agree to limit consumption of alcohol to no more than 7 drinks* and males 
agree to limit consumption of alcohol to no more than 14 drinks* a week  for the duration 
of the study  
17) Females of childbearing potential, agrees to use one of the following methods of 
contraception throughout the study: licensed hormonal method , intrauterine  device, 
condoms with contraceptive foam, abstinence, or  vasectomy in partner  (if 
post-menopausal, must not have menstruated  for at least 12 consecutive months ) 
18) Willing and able to understand and  comply with all study procedures and be available 
for the duration of  the study  
4.2 Participant  Exclusion Criteria  
A potential participant  who meets  any of the following criteria will be excluded from enrollment 
and randomization: 
1) Has a  history of congestive heart failure or the presence of any of the following 
cardiovascular conditions: clinically significant abnormal 12 -lead ECG, sinus 
bradycardia (resting heart rate below 55 beats per minute  although lower heart rates 
will be acceptable upon the review and approval by the site cardiologist ), greater than 
first degree heart b lock, coronary artery disease , uncontrolled hypertension, or 
hypotension ( systolic  blood pressure below 90 mm Hg) . In individuals  with a heart rate 
below 55 beats per minute, th e site cardiologist will review the participant’s  medical 
history, including any concomitant medications, to ensure that they are in good general 
health and have no medical  contraindications to taking propranolol . 
2) Has any of the following medical conditions: bronchial asthma, nonallergic  
bronchospasm  (chronic obstructive pulmonary di sease and emphysema ), renal failure 
or dialysis, diabetes mellitus, hyperthyroidism, fibromyalgia, or uncontrolled seizures  
3) Has k nown hypersensitivity to propranolol  or components of the placebo capsules  
4) Currently taking  a β-block er or medication that may interact with propranolol, including 
haloperidol, intravenous verapamil, and catecholamine- depleting drugs, such as 
reserpine, within 30 days prior to the Screening and B aseline Visit   
5) Currently  taking an opioid medication, whether  episodically or daily , within 30 days prior 
to the Screening and B aseline Visit 
6) Has commenced a new daily prescription medi cation  for the management of  pain within 
30 days prior to the  Screening and B aseline Visit 
                                                
* one standard drink  is define d as 12 ounces of regular beer, 5 ounces of wine, or 1.5 ounces of 80 proof 
distilled spirits.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
30 7) Used any injection therapy (e.g., tender or trigger point injections, steroid injections) for 
the management of pain within 2 weeks prior to the S creening and B aseline Visit  
8) Used acupuncture, biofeedback , or TENS for the management of pain within 2 weeks 
prior to the Screening and B aseline Visit 
9) Has commenced  occlusal splint  therapy for the management  of facial pain within 
30 days prior to the S creening and B aseline Visit 
10) Has experienced facial trauma or orofacial surgery within 6 weeks  prior to the 
Screening and B aseline Visit 
11) Is undergoing current active orthodontic treatment (passive retainers are permitted)  
12) Has a history of major depression or other major psychiatric disorder requiring 
hospitaliz ation within the last 6 months  prior to the Screening  and Baseline Visit 
13) Has a history of treatment for drug or alcohol abuse within the last year  
14) Has scored 8 or more on the Alcohol Use Disorders Identification Test (AUDIT) at the 
Screening and B aseline Visit 
15) Currently smokes at least  25 cigarettes per day  
16) Current ly being treated with chemotherapy or radiation therapy  
17) Has been treated with another investigational drug or treatment  within 30 days prior to 
the Screening and B aseline Visit 
18) Is pregnant or nursing 
19) Anything that, in the opinion of the investigator, would place the participant  at 
increased risk or preclude the participant ’s full compliance with or completion of the 
study  
4.3 Strategies for Recruitment and Retention 
Participant s will be recruited from existing TMD patient registries and from various clinics at the 
three universities.  Clinicians  at these sites will be made aware of the study and asked to inform 
their patients of the study and to provide their patients  with study contact information.  In 
addition, participant s may be recruited through print and electronic media advertisements . All 
recruitment materials will be submitted to the I nstitutional Review Boards ( IRBs)  for review and 
approval prior to their use.  
Participant s will be reminded of each upcoming visit  by telephone, text  message, email, or 
letter. Participant s will be told about the importance of keeping each scheduled appointment, 
and they will be instructed to contact the study staff as soon as possible if they are unable to 
attend a sch eduled appointment. Participant s who miss a scheduled visit without notifying the 
study staff will be contacted by one of the previous ly mentioned methods to encourage their 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
31 continued participation in the study and to ask them to contact the study team con cerning their 
next appointment . Unscheduled visits may occur at the investigator’s discretion ( Section 6.6). 
Participants will be compensated for their participation in the study in an amount stated in the 
informed consent form, and in some cases, the participant may be eligible for reimbursement of 
some travel expenses.  
4.4 Treatment Assignment Procedures  
4.4.1  Randomization Procedures  
Prior to randomization, the inclusion and exclusion criteria will be reviewed, and any participant 
who does not meet the criteria with be discontinued from the trial. Randomization will be  
stratified  across 3  clinic al sites for a total of 200 randomized participants . Within each site, 
participant s will be randomized in a 1:1 ratio of active drug to placebo within prespecified blocks. 
Randomization wil l be accomplished by a web- based randomization system devel oped and 
maintained by the data coordinating center. At the time of randomization, study staff, who will 
remain blind ed to treatment assignment, will access the system, enter the participant ’s study 
identification number, and verify that the participant  is eligible for randomization. The system will 
assign a randomization code that will indicate to the pharmacy the participant’s treatment assignment.  
4.4.2  Blind ing Procedures  
All study staff, including the study clinicians and investigators, will be blind ed to the participant s’ 
treatment assignment s throughout the data collection peri od. Propranolol hydrochloride 
extended- release capsules will be over -encapsulated and cannot be differenti ated from the 
placebo capsules  by appearance alone. The research pharmac ies will be unblinded. The data 
coordinating center ( DCC ) project staff will remain blind ed through the analysis for the primary 
objective. If oversight boards, such as the IRBs or Data and Safety Monitoring Board ( DSMB ), 
request  an unblinded data report during the data collection period, an unblinded biostatistician 
at the DCC will generate the report . 
4.4.3  Unblinding Procedures  
Unblinding  before the study is completed will occur only if a participant ’s well- being is 
threatened and is necessary to protect the participant . Except in extreme medical emergencies, 
before the treatment  assignment for a participant  is unblinded, the investigator must confer with 
the National Institute of Dental and Craniofacial Research ( NIDCR) m edical monitor  and the site 
cardiologist as necessary . For extreme medical emergencies that occur during business hours , 
the clinical site investigator will contact the DCC to determine the participant ’s treatment 
assignment . For extreme medical emergencies that occur outs ide of business  hours, medical 
personnel will contact the site pharmacy to determine the  participant’s treatment assignment. An 
event is considered an extreme medical emergency when appropriate medical management of 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
32 the participant  necessitates knowledge of treatment assignment. Study participants will be 
provided with instructions and contac t information for emergency situations. The emergency 
unblinding  will be recorded and reported to the PI and to the NIDCR medical monitor as soon as 
possible. A full account of the event will be recorded, including the date and time of the 
emergency, the reason for unblinding, and the names of the medical monitor and others who 
were notified of the emergency.  The unblinding will be reported to the DSMB and the IRBs 
according to reporting guidelines for those boards . 
4.4.4  Reasons for Participant  Withdrawal  
Participant s are free to withdraw from participation in the study at any time, and the investigator 
may withdraw a participant  for any of the following reasons : 
• Withdrawal of consent .  
• Does not meet criteria for randomization.  
• Pregnancy .  
• Continued participation deemed to be not in the participant’s best interest . 
• Investigator discretion.  
Participants requiring significant surgery will be withdrawn from the protocol . Investigators will 
use discretion in making this determination. Participants withdrawn after randomization will not 
be replaced.  If a participant does not return for a scheduled visit, every effort should be made to 
contact the participant  and document the outcome. If the participant withdraws consent, no 
further evaluations will  be performed, and no attempts will be made to collect additional data.  
4.4.5  Handling of Withdrawals  and Discontinuation 
Participant s who withdraw from the study voluntarily or are withdrawn by an investigator will be 
discontinued from the study. Study staff will complete a study disposition form in the electronic 
data capture  (EDC) system, indicating the reason for discontinuation. If the participant  is on 
study drug at discontinuation, the investigator s, in consultation with the site cardiologist , will 
decide the following: (1) the need for tapering of the investigational drug, ( 2) whether tapering 
will be conducted by the investigator prior to discontinuation or by a referring practitioner  after 
discontinuation, and (3) whether unblinding  of the treatment assignment will be required.  If 
unblinding  is required, the investigator will follow the unblinding  procedures described in Section 
4.4.3 . 
Any participant  with an AE that is ongoing at the time of discontinuation will be followed until the 
event returns to baseline, resolves, or stabilizes. If the AE does not meet these outcomes within 
30 days after discontinuation or the end of the study, the participant  will be referred to an 
appropriate practitioner for continued care.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
33 4.4.6  Suspension or Termination of the Study  
The study may be suspended or prematurely ter minated by the NIDCR if reasonable cause 
exists , as determined by the PI, the NIDCR p rogram official or medical monitor , the IRB, or the 
DSMB . Circumstances that may warrant suspension or termination include, but are not limited 
to, the following:  
• Determi nation of unexpected, significant, or unacceptable risk to participant s.  
• Insufficient adherence to protocol requirements .  
• Data that are insufficient and/or not evaluable. 
If the study is prematurely suspended or terminated, the PI will provide written notification to the 
investigators, the NIDCR program official, the IRB, and the DSMB.  
5 STUDY INVESTIGATIONAL PRODUCT AND P LACEBO 
The Investigators consulted with the FDA to determine whether  this protocol should be 
conducted under an I ND. The FDA determined that this clinical trial meets the exemption 
requirements for an IND. An overview of the investigational product and placebo are provided 
below ; further details are available in the Manual of Procedures  (MOP) . 
5.1 Investigational  Product  
The investigational product is propranolol hydrochloride extended- release  capsules , an 
approved drug for the treatment of hypertension, angina pectoris due to c oronary 
atherosclerosis , migraine, and hypertrophic subaortic stenosis . The package insert for  
propranolol hydrochloride extended-r elease  is provided in Appendix B. Propranolol 
hydrochloride extended- release is a nonselective β -adrenergic receptor -blocking agent. The 
extended- release formula provides  a sustained releas e of propranolol hydrochloride.  
5.1.1  Acquisition 
Propranolol hydrochloride extended- release  60 mg capsules will be acquired from a 
compounding pharmacy  and shipped to the research pharmacy at each clinical site. The  
research pharmacies will dispense the drug . 
5.1.2  Formulation, Packaging, and Labeling  
The propranolol hydrochloride extended- release  capsules will be over -encapsulated by the 
compounding  pharmacy to have the same appearance as the placebo. Neither the study 
personnel nor the study participants will be able to different iate the study drug from the placebo 
by appearance alone.    
The res earch pharmacy will label and dispense the 60 mg capsules  in tight, light -resistant 
container s. The conta iners will be labeled with the following information:  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
34 • Name and address of the dispensing pharmacy  
• Protocol number  
• Name of the drug labeled as “ propranolol hydrochloride extended- release  or placebo”  to 
protect the blinding  
• Strength of the drug  (60 mg propranolol hydrochloride extended- release or placebo) and 
number of capsules dispensed 
• Name of the prescribing clinician  
• Instructions for use  
• Participant  name and medical  record number  
• Date dispensed  
• The following statement: “Limited by Federal Law to I nvestigational Use Only” 
5.1.3  Product Storage and Stability  
Propranolol hydrochloride extended- release  capsules will be shipped and stored  according to 
United States Pharmacopeial Convention (USP) Controlled Room Temperature guidelines and 
protected from  light, moisture , freezing, and excessive heat.  
5.2 Dosage  and Administration of Investigational Product  
Propranolol hydrochloride extended- release  60 mg capsules will be dispensed at Visits 1, 2, 3, 
and 4 as described below : 
• Visit 1 (beginning of the 1- week  titration ): 1 capsule per day  in the evening 
• Visit 2 (beginning of the first  4 weeks of  maintenance):  2 capsules per day, one in the 
morning and one in the evening  
• Visit 3 (beginning of the last 4 weeks of  maintenance):  2 capsules per day, one in the 
morning and one in the evening  
• Visit 4 (beginning of the 1- week tapering ): 1 capsule per day  in the evening 
5.3 Modification of Dosage of Investigational Product  
If a participant cannot tolerate the  scheduled titration or maintenance dosage, they will remain in 
the study at either a lower, tolerated dosage or without taking study medication. These events 
will be recorded as protocol deviations.   
5.4 Placebo  
The placebo, which will be manufactured for this study , will be acquired, packaged, labeled, 
dispensed, and administered in the same manner as described above for the active drug. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
35 Ingredients will be a microcrystalline cellulose filler and a gelatin capsule. S torage requirements 
for the pla cebo are the same as for the active drug.  
5.5 Accountability Procedures  
The research pharmac ies will be responsible for maintaining either paper or el ectronic logs for 
the acquisition  and dispensing of the active drug and placebo. The pharmac ies will also be 
responsible for maintaining and monitoring storage conditions for the active drug and placebo. 
The logs and records of storage conditions will be reviewed by the clinical monitor during 
periodic monitoring visits.  
5.6 Assessment of Participant  Compliance  
Participant s will be asked to bring their medication containers to each visit during the treatment 
period. Study staff will count the number of capsules  returned and will enter the number on a 
case report form  in the EDC  system. Participants will record the study medication use in t he 
Daily Symptom Diary  that will be reviewed by the study staff at Visit s 2, 3, 4, and 5 . Participant 
compliance with study medication will be defined as  taking 60% or more of the study medication 
for the duration of the study.  
5.7 Concomitant Medications  and Therapies  
Prior and concomitant medication information will be collected for all participant s for the  30 days 
prior to the Screening and B aseline V isit and during the study. Information collected will include 
medication, total daily dose, start date, stop date (if applicable), and primary reason for use.  
Information about treatment with injection therapy, acupuncture, biofeedba ck, TENS, and 
occlusal  splint  therapy will also be collected for all participants for the 30 days prior to the 
Screening and Baseline V isit and during the study.  
5.7.1  Rescue Medication  
Rescue medic ations described below may be used to alleviate pain. Episodic use of a rescue 
medication will be defined as use for  no more than 3 consecutive days and for no more than 
18 total days from Visits 1 to 4 . 
5.7.1.1  Over -the-counter medications  
NSAID s are most often used to manage pain in TMD patients. If a participant is taking an over -
the-counter medication daily  for pain management , the participant will be encouraged to 
continue the same usage of that medication throughout the study. The usage of short -acting, 
non-prescription analgesics ( e.g., NSAIDs , aspirin, and/or acetaminophen)  by participants 
during the study will be recorded and quantified at each visit , and the usage will be classified as  
either daily or episodic .  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
36 5.7.1.2  Prescription medications 
Participants who enter the study on a daily regimen of a prescription medication for pain will be 
encouraged to continue that regimen throughout the study. The usage of  all prescription 
medications for pain during the study  will be recorded and quantified at each visit . 
5.7.2  Nonpharmacological Therapy  
During the course of the trial, participant s will not be restricted in the use of  the 
nonpharmacological therapies , with the exception of acupuncture, biofeedback, and/or TENS . If, 
contrary to the study requirements , a participant start s acupuncture, biofe edback, and/ or TENS 
treatment for the management of pain during the study, t he use of these therapies will be 
recorded .  
5.8 Protocol Deviations Related to the Use of Investigational 
Product and Concomitant Therapies  
The following protocol deviations related to the use of investigational product and concomitant 
therapies will be considered major protocol deviations and reported on a case report form in the 
EDC system. 
• Participant is unable to reach the maintenance dosage of the study drug or placebo or is 
unable to remain on the maintenance dosage. 
• Initiation of opioid medications.  
• Initiation of TMJ surgical treatment (including TMJ arthrocentesis). 
• Initiation of  therapeutic injections  for the management of pain. 
• Initiation of occlusal splint  therapy . 
• Initiation of any of the following nonpharmacological therapies: acupuncture, biofeedback, and/or TENS.  
• Initiation after Visit 1 and usage of short -acting, non- prescription analgesics 
(e.g., NSAIDs, aspirin, and/or acetaminophen)  for pain that exceeds the definition of 
episodic use as described in Section 5.7.1 . 
6 STUDY SCHEDULE 
The Schedule of Events table, which provides an overview of the study phases, timeline, and 
events  by visit,  is provided in Appendix A. In the following  section, events  are listed by study 
phase and visit , though the order of events listed within a visit does not imply the order in which 
the event s will occur. A description of the procedures is provided i n Section 7 . 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
37 6.1 Prescreening  (Day -49 to Day -7) 
Prescreening may occur by telephone or at a clinic visit, and it may be combined with the 
Screening and Baseline Visit (Visit 0). After obtaining verbal consent, a  brief prescreening 
interview script will be administered  and basic eligibility information, specific points  of medical 
history, and contact information will be recorded . If a participant  expresses interest in the study 
and if the participant  is eligible, the participant  will be scheduled for Visit 0 within 4  weeks . 
6.2 Screening and Baseline Visit 0 (Day -21 to Day -7) 
The following procedures and assessments will be conducted up until the time of screen failure : 
1) Obtain consent for study participation  
2) Obtain consent to store biological specimens for future studies  
3) Obtain signed Health Insurance Portability and Accountability  statement (as 
applicable)  
4) Collect demographic information 
5) Obtain medical history  
6) Administer the AUDIT Questionnai re 
7) Administer the Smoking Questionnai re 
8) Administer the Symptom Inventory  
9) Record concomitant medications  
10) Record specified concomitant therapies  
11) Collect physical measurements  
12) Collect vital signs  
13) Perform a urine pregnancy test in female participants of childbearing potential  
14) Administer the Fibromyalgia Questionnaire 
15) Perform the m anual tender point examination 
16) Administe r the SF-McGill Pain  Questionnaire  
17) Perform TMD examination 
18) Review eligibility criteria  
19) Perform pressure and heat pain tests  (baseline data)  
20) Dispense outcome measure questionnaires as shown in Schedule of Events  
21) Dispense new Daily Symptom Diaries  
22) Schedule next visi t 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
38 23) Perform a  screening  ECG  
6.3 Treatment (Visits 1-4) 
6.3.1  Randomization and Titration V isit 1 (Day 0) 
The following procedures and assessments will be conducted  at Visit 1: 
1) Review medical history  
2) Record the average number of alcoholic drinks consumed per week since the previous 
visit 
3) Administer the Symptom Inventory  
4) Record concomitant medications  
5) Record specified concomitant therapies  
6) Assess and record AEs  
7) Collect vital signs  
8) Collect Daily Symptom Diaries  
9) Assess compliance with Daily Symptom Diaries  
10) Collec t outcome measure questionnaires as shown in Schedule of Events  
11) Perform a urine pregnancy test in female participants of childbearing potential  
12) Review eligibility criteria  
13) Collect confidence in treatment outcome data 
14) Perform randomization to study drug, if participant is eligible  
15) Draw blood  
16) Dispense new Daily Symptom Diaries  
17) Schedule next visit  
18) Dispense study drug 
At least 4 entries in the Daily Symptom Diary must be completed satisfactorily within the week preceding this visit for the participant  to meet the eligibility criterion for randomization. The 
participant  must also have an average pain intensity score of ≥ 30 or reports a rating of average 
daily pain intensity of ≥  30 on ate least 3 days in the preceding week, as calculated from the 
Daily  Symptom Diary entries, to meet the eligibility criteria. If a participant  meets  these 2 
eligibility criteria during this visit, the participant  will be randomized and continue in the study.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
39 6.3.2  Maintenance V isit 2 (Day 7 [+ 3 days ]) 
The following procedures and assessments will be conducted at Visit 2: 
1) Collect study drug containers issued at  previous visit  
2) Collect Daily Symptom Diaries  
3) Assess participant compliance with Daily Symptom Diaries   
4) Review medical history  
5) Record the average number of alcoholic drinks  consumed per week since the previous 
visit 
6) Administer the Symptom Inventory  
7) Record concomitant medications  
8) Record specified concomitant therapies  
9) Assess and record AEs  
10) Collect vital signs  
11) Perform a urine pregnancy test in female participants of childbearing potential  
12) Administer the SF -McGill Pain Questionnaire  
13) Dispense new Daily Symptom Diaries  
14) Dispense study drug 
15) Schedule next visit  
16) When participant has left, assess participant compliance with study drug usage  
6.3.3  Maintenance V isit 3 (Day 35 [± 7 days ]) 
The following procedures and assessments will be conducted  at Visit 3 : 
1) Collect study drug containers issued at previous visit  
2) Collect all Daily Symptom Diar ies (each diary covering one week)   
3) Assess participant compliance with Daily Symptom Diaries   
4) Review medical history  
5) Record the average number of alcoholic drinks consumed per week since the previous 
visit 
6) Administer the Symptom Inventory  
7) Record concomitant medications  
8) Record specified concomitant therapies  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
40 9) Assess and record AEs  
10) Collect vital signs  
11) Perfo rm a urine pregnancy test in female participants of childbearing potential 
12) Perform TMD examination 
13) Perform heat and pressure pain tests  
14) Administer outcome measure questionnaires as shown in Schedule of Events  
15) Dispense new Daily Symptom Diaries  
16) Dispense study drug 
17) Schedule next visit  
18) When participant has left, assess participant compliance with study drug usage  
6.3.4  Tapering Visit 4 (Day 63 [+6 days ]) 
The following procedures and assessments will be conducted  at Visit 4 : 
1) Collect study drug containers issued at  previous visit  
2) Collect all Daily Symptom Diar ies (each diary covering one week)  
3) Assess participant compliance with Daily Symptom Diaries  
4) Review medical history  
5) Record the average number of alcoholic drinks consumed per week since the previous 
visit 
6) Administer the Symptom Inventory  
7) Record concomitant medications  
8) Record specified concomitant therapies  
9) Assess and record AEs  
10) Collect vital signs  
11) Perform a urine pregnancy test in female participants of childbearing potential  
12) Perform TMD examination 
13) Perform heat and pressure pain tests  
14) Administer outcome measure questionnaires as shown in Schedule of Events  
15) Dispense new Daily Symptom Diaries  
16) Dispense study drug 
17) Draw blood  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
41 18) Schedule next visit  
19) When participant has left, assess participant compliance with study  drug usage  
6.4 Follow -up Visit 5 (Day 77 [+ 7 days ]) 
The following procedures and assessments will be conducted  at Visit 5 : 
1) Collect study drug containers issued at  previous visit  
2) Collect Daily Symptom Diaries  (each diary covering one week)  
3) Assess participant compliance with Daily Symptom Diaries   
4) Review medical history  
5) Administer Smoking Questionnaire  
6) Record the average number of alcoholic drinks consumed per week since the previous 
visit 
7) Administer the Symptom Inventory  
8) Record concomitant medications  
9) Record specified concomitant therapies  
10) Assess and record AEs  
11) Collect vital signs  
12) Perform a urine pregnancy test in female participants of childbearing potential  
13) Administer the SF- McGill Pain Questionnaire  
14) When participant has left, assess participant compliance with study drug usage  
6.5 Early Termination Visit  
If a participant  is discontinued before study completion,  prior to the withdrawal of consent  and 
with the participant ’s permission , an E arly Termination Visit may be conducted, either during a 
scheduled or unscheduled visi t. Each of the procedures  and assessments described for Visit 4 
(Section 6.3.4 ) and the administration of the Smoking Questionnaire will be conducted at the 
Early Termination Visit.  
6.6 Unscheduled Visit  
An unscheduled visit may occur at the discretion of the investigator. Reasons for an unscheduled visit would include, but are not limited to,  an AE, the inability of the participant  to 
attend a visit within the visit window , or the need for an E arly Termination  Visit. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
42 7 STUDY PROCEDURES 
Standard operating procedures  for all study procedures will be  detailed in the MOP , which will 
be provided to study staff prior to study start -up. Overviews of the procedures  are provided 
below . Data collected during these procedures will be entered into case report forms within the 
EDC system or via Teleform.  
7.1 Clinical Evaluations  
7.1.1  Medical History  
The medical history for each participant will be obtained by interview  and entered into the case 
report form . Medical hi story will be updated at each visit.  
7.1.2  Vital Signs and Physical Measurements  
After the participant  has rested in a chair for 10 minutes, trained personnel will take 3 readings 
of the particip ant’s systolic blood pressure, diastolic blood pressure, and heart rate at 2 -minute 
intervals. A physical examination will be performed at the Screening and Baseline Visit (Visit 0) 
and will include height and weight measurements.  
7.1.3  Pregnancy Test  
Because propranolol hydrochloride extended- release is not recommended  for use during 
pregnancy ( Appendix B ), female participant s of childbearing potential will have a urine 
pregnancy test (instant type) performed at all visits . The res ults will be read by a member of the 
study staff. The urine will be discarded after the test.  
7.1.4  Blood Draw  
Staff trained in phlebotomy will obtain up to 20  milliliters of blood by venipuncture . Two whole 
blood tubes for DNA analyses  will be placed in short -term storage at each site at 4ºC, and  
2 additional whole blood tubes will be processed to obtain plasma and red blood cells. Plasma 
and red blood cells for future cytokine  and COMT  activity analyses will be divided into aliquots 
and placed in storage along with the tubes for DNA analyses at -80ºC at each site until shipping 
to the facilities that will perform DNA extraction ( Section 7.2.3 ). 
7.1.5  Electrocardiogram  
Trained personnel  will administer a 12 -lead ECG. The procedure involves having the participant  
lie prone on an examination table and placing electrode stickers on the participant ’s skin. The 
original ECG will be reviewed by a cardiologist. At  the U niversity of N orth Carolina (UNC) , the 
ECG will be performed at the Clinical and Translational Research Center, and at the University 
of Florida (UF), the ECG will be performed at the Clinical Research Center . 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
43 7.1.6  Temporomandibular Disorder Examination  
Trained and calibrated study staff will perform  a TMD e xamination based on the Diagnostic 
Criteria for Temporomandibular Disorder (DC /TMD) .36 The e xamination assesses pain in 
masticatory muscles and  the TMJ in response to palpat ion and maneuvering of the jaw. The 
examiner will bilaterally palpate the  extraoral masticatory muscles (temporalis  and masseter)  
and TMJ. For eligibility, the participant  must meet 2 criteria  relating to TMD : 1) reported pain or 
ache in the jaw, temple, face, preauricular area , or inside the ear that is changed by jaw 
function; and 2) finding(s) of TMD myalgia classified according to the  DC/TMD criteria during the 
examination.  
7.1.7  Tests for Heat Sensitivity  
Trained study staff will perform the heat sensitivity tests. Contact heat stimuli will be delivered 
using a computer -controlled thermal sensory analyzer  as described in the MOP. Thermal 
threshold and tolerance will be measured on the ventral forearm by an ascending method of 
limits. T he thermal pain threshold will  be defined as the temperature at which the participant first 
perceives heat pain, whereas thermal pain tolerance will be defined as the temperature at which 
the participant  can no longer tolerate the pain. The temperature will increase from a baseline of 
32°C with a 0.5° C/s rate of rise until the participant  responds by pressing the button. The c utoff 
temperature for both measurements will be 50°C. Average thermal threshold and tolerance will 
be calculated from 4  assessments conducted with a 5- second interstimul us interval at different 
sites of the ventral forearm.  For all heat tests, participants  will be first given practice runs on a 
site distant from subsequent testing to ver ify the participant’s understanding of the protocol. 
7.1.8  Pressure Pain Threshold Measurements  
Trained study staff will perform the PPT  measurements . The PPT will be assessed bilaterally 
over the temporalis , masseter , and trapezius  muscles , the TMJs , and the lateral epicondyles  
with a pressure algometer  as described in the MOP . The PPT will be defined as the amount of 
pressure at which the participant  first perceive s the stimulus to be painful. One pre- trial 
assessment will be performed at each site followed by additional assessments until 2 measures 
differing by less than 0.2 kg are obtained , or 5 assessments a re administered. In either case, 
the mean of the 2 closest values will be reco rded as the threshold estimate. Pressure stimuli will 
be delivered at an approximate rate of 1 kg/s. The cutoff pressure for all sites will be 5 kg. The 
values from the right and left sides will be averaged to obtain a single  PPT value per anatomical 
site. 
7.1.9  Manual Tender Point  Examination  
The manual tender point examination will be performed by trained study staff, as a screening 
procedure . This assessment verifies a report of pain at a minimum of 11 of 18 specific locations 
(tender points) , when palpated with approximately 4 kg of digital pressure. The 18 sites (9 pairs) 
examined are identical to those defined in the American College of Rheumatology (ACR) criteria 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
44 for the classification of fibromyalgia ( 1990),37 which require a history of widespread pain present 
for at least 3 months with pain in 11 of 18 tender point sites on digital palpation. Pain is 
considered widespread when all of the following are present: pain in the left side of the body, 
pain in the right side of the body, pain above the waist, and pain below the waist. In addition, 
axial skeletal pain (cervical spine, anterior chest , thoracic spine, or low back) must be present. 
In this definition, shoulder and buttock pain is considered pain for each involved side. Low back  
pain is considered lower segment pain. Digital palpation should be performed with an approximate force of 4 kg. For a  tender point to be considered positive , the participant  must 
state that the palpation was “painful” ; “tender” is not considered painful. For classification 
purposes, participant s will be said to have fibromyalgia and be ineligible for study participation i f 
both criteria ar e satisfied . 
Pain, on digital palpation , must be present in at least 11 of the following 18 tender point sites: 
1) Occiput (bilateral, at the suboccipital muscle insertions)  
2) Low cervical (bilateral, at the anterior aspects of the intertransverse spaces at C5- C7) 
3) Trapezius (bilateral, at the midpoint of the upper border)  
4) Supraspinatus (bilateral, at origins, above the scapula spine near the medial border)  
5) Second rib (bilateral, at the second costochondral junction, just lateral to the junctions 
on upper surfaces)  
6) Lateral epicondyle (bilateral, 2 cm distal to the epicondyles)  
7) Gluteal (bilateral, in upper outer quadrants of buttocks in anterior fold of muscle)  
8) Greater trochanter (bilateral, posterior to the trochanteric prominence)  
9) Knee (bilateral, at the m edial fat pad proximal to the joint line)  
7.1.10  Daily Symptom Diary  
The participant s will be asked to complete the Daily Symptom Diary  at the end of each day 
starting at Visit 0 and ending at Visit 5. Participants who complete at least 4 out of the 7 entries 
per week at V isit 1 will be considered eligible for study participation.  The diary requests 
information about the participant ’s pain intensity (reported on a 0- 100 numeric rating scale) and 
duration ( reported on a 0 -100 percentage scale), fatigue, sleep, and somatic symptoms. The 
participants will complete  a Daily Symptom Diary on a new paper form each week of the study , 
as described in the MOP . The participant s will return paper -based diaries either by mail or in 
person at study visits. Compliance with the Daily Symptom Diary will be defined as completion 
of at least 4 daily entries within 7 days . Any noncompliance found during  Visits 2 through 5 will 
be reported as protocol deviations. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
45 7.1.11  The Alcohol Use Disorders Identification Test 
The Alcohol Use Disorders Identification Test is a method to screen for excessive drinking . 38  
This questionnaire assesses recent alcohol use, alcohol dependence symptoms and alcohol -
related problems.  The AUDIT test will be performed at V 0, as described in the MOP. 
Participants with a score of 8 or more will be ineligible for study participation. 
7.1.12  Smoking Questionnaire  
The Smoking Questionnaire is a method to screen for use of and exposure to tobacco smoke. 
This questionnaire ass esses  current and former use of combustible and smokeless tobacco, as 
well as current exposure to environmental tobacco smoke. The questionnaire will be 
administered at V isit 0 and V isit 5, as described in the MOP. Participants  who self -report 
smoking  at least 25  cigarettes per day at Visit 0 will be ineligible for study participation. 
7.1.13  Symptom Inventory  
The Symptom Inventory is a method to screen for AEs. Trained study staff will record participant 
responses to questions about the occurrence and severity of expected AEs known to be 
associated with propranolol hydrochloride extended- release. The Symptom Inventory will be 
administered at all visits, as described in the MOP . If a symptom has emerged or worsened, 
study personnel will evaluate the symptom for a possible AE.   
7.1.14  Outcome Measure Questionnaires  
The questionnaires  that will be utilized  are lis ted in the Schedule of Events ( Appendix A ) and 
are briefly described below . Copies of the questionnaires are reproduced in t he attachments . 
Several questionnaires are self -administered , and others will be administered by trained study 
staff. For outcome measure questionnaires, responses will be recorded on paper  Teleform case 
report forms , which will be scanned as  described in the MOP .  
Short -Form McGill Pain Questionnaire . This questionnaire consists of 15 descriptors 
(11 sensory , 4 affective) which are rated on an intensity scale as 0 (“ none”) , 1 (“mild”), 
2 (“moderate ”), or 3 (“ severe ”).39 
Graded Chronic Pain Scale (GCPS) . The GCP S comprises 7 items and assesses 2 dimens ions 
of pain: pain intensity and pain- related disability.7, 40 
Fibromyalgia Questionnaire. This q uestionnaire  assesses the ACR criteria for fibromyalgia 
(1990)37 and includes pain- related questions and manikin drawing s of participant  pain location.  
Short Form 12 Health Survey Version 2 (SF-12 v2) . The SF-12 v2 is a briefer measure of 
health- related quality of life derived by using 12 items from the original Short Form 36 
instrument.41 This questionnaire produces 2 scores: a mental health composite score and a 
physical health composite score . 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
46 Patient Global Impression of Change  (PGIC) . The PGIC is a participant -rated instrument that 
measures change in participant ’s overall st atus on a scale ranging from 1 (“very much 
improved”) to 7 (“very much worse”) . The PGIC is based on the Clinical Global Impression of 
Change, which is a validated scale .42 
Jaw Functional  Limitation Scale . This 20-item instrument measures limitations across 
3 domains: mastication (6 items), vertical jaw mobility (4 items), and verbal and emotional 
expression (8 items) .43, 44 Two items are not scored as part  of these 3 subscales. A degree o f 
limitation is rated on a 0-10 scale from 0 (“ no limitation” ) to 10 (“severe limitation ”). 
Perceived Stress Scale. This questionnaire assesses 1 4 sources of stress and produces an 
overall  perceived stress rating.45 
Hospital Anxiety and Depression Scale. This 14-item instrument evaluates  anxiety  and 
depression.46 
Symptom Checklist 90 -Revised (SCL -90R) Somatization Subscale.  The somatization subscale 
of the SCL-90R assesses a degree of somatic symptoms experienced by participant s. It 
contains 12 items.47   
Pittsburgh Sleep Quality Index . This 19-item instrument assesses sleep quality during the 
previous month across several domains: subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sleep disturbances, use of sleep m edication, and daytime 
dysfunction.48 
Coping Strategies Questionnaire Revised  (CSQ -R). The CSQ -R consists of 27 items relating to 
how individu als cope with pain. Participants indicate the frequency with which they engage in 
specific coping activities when experiencing pain, using a 7- category numerical scale ranging 
from 0 (never do that) to 6 (always do that). It y ields 6 subscales  reflecting the pain coping 
strategies that individua ls use: diverting attention, catastrophizing, praying and hoping, ignoring 
pain sensations, reinter preting pain sensations, and coping self -statements.49 
Headache Questionnaire . This questionnaire assesses diagnostic criteria for tension- type 
headache and migraine according to the International Classification of Headache Disorders 3 
(beta version) . 50 
Headache Impact Test (HIT- 6). The HIT -6 evaluates the factors contributing to the burden of 
headache and consists of 6 items: pain, social functioning, role functioning, vitality, cognitive 
functioning, and psychological distress.51 The participant  answers each question using 
responses ranging from “never” to “always.” These responses are summed to produce a total 
HIT-6 score.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
47 7.2 Laboratory Evaluations  
7.2.1  Clinical Laboratory Evaluations  
In this study, clinical laboratory tests  are not needed for the monitoring of s afety or the 
evaluation of study objectives; therefore, none will be perfor med. 
7.2.2  Research Laboratory  Evaluations  
DNA extracted from whole blood samples will be analyzed for polymorphisms including, but not 
limited to the COMT , ADRB2 , and ADRB3  genes . DNA , plasma, and red blood cells  will be 
stored for possible future  IRB-approved genetic, cytokine, and COMT  activity analyses (Section 
14.5).  
7.2.3  Specimen Preparation, Handling, and Shipping 
Standard operating procedures for specimen collection, p reparation, handling, shipping, 
storage, and analysis will be provided in the MOP . The shipping and storage of all samples will 
be tracked by a web- based specimen tacking system programmed and maintained by the DCC. 
DNA.  Whole blood samples for DNA analyses will be collected and stored at - 80ºC . Whole 
blood s amples collected at UF and UB will be shipped in batches to UNC. Genomic DNA will be 
purified from whole blood samples and stored at -80ºC  until genotyping is performed  and for 
future use .  
Future Use.  Plasma and red blood cells for future cytokine and COMT  activity analyses will be 
divided into aliquots and placed in short -term storage at -80ºC at each site.  Plasma and red 
blood cells samples collected at UF  and UB  will be shipped in batches to UNC. 
8 ASSESSMENT OF SAFETY  
8.1 Specification of Safety Parameters  
Participants  in this study will undergo close follow -up. As described in Section 2.3, risks related 
to participation include: 1) risks related to the administration of propranolol hydrochloride 
extended- release; 2) risks related to the administration of the ECG; 3) risks associated with 
questionnaires; 4) risks associated with TMD e xaminations and psychophysical tests; 
5) well-known and anticipated minor risks from venous phlebotomy; and 6) risks related to study 
participation such as loss of confidentiality of collected data. 
The risks described above will  be characterized and monitored to protect the safety of 
participant s. In addition, the study has been designed to minimize risks. Participants  will be 
monitored closely for AEs with frequent  visits.  Adverse events will be managed  by the site 
dentist or site cardiologist  depending on the nature of the event.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
48 Examination and close follow -up of parameters capturing participants’  overall health will be 
collected on case report forms. These will be completed at every study visit, and data will be 
compiled into a prespecified format and reviewed by the DSMB ( Section 9). 
As part of the study outcomes, study personnel will collect the occurrences of the following 
expected AEs know n to be associated with propranolol hydrochloride extended- release: 
• Dizziness or lightheadedness  
• Unusual tiredness or f atigue 
• Nausea or vomiting  
• Upset stomach  
• Hands numbness or tingling  
• Sleep problems  
• Depression 
In this study , the following expected events will not be considered reportable AEs: 
• Minor bleeding or bruising resulting from the blood draw  
• Temporary pain or temporary increases in existing pain elicited dur ing the TMD clinical 
examination or tests of heat, pressure, or tender points  
• Worsening of TMD signs and symptoms during the participant’s 12- to 15- week 
participation  
8.1.1  Unanticipated Problems  
The Office for Human Research Protections (OHRP) considers unanticipated problems  (UPs) 
involving risks to participants  or others to include, in general, any incident, experience, or 
outcome that meets all  of the following criteria:  
• Unexpected (in terms of nature, severity, or frequency) given (a) the research 
procedures that are described in the protocol -related documents, such as the 
IRB-approved research protocol and informed consent document and (b) the 
characteristics of the participant  population being studied; 
• Related or possibly related to participation in the research (in the guidance document, 
possibly related means there is a reasonable possibility that the incident, experience, or 
outcome may have been caused by the procedures involved in the research);  
• Suggests that the research places participant s or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was previously known 
or recognized.  
8.1.2  Adverse Event s 
The International Conference on Harmonisation ( ICH) Guideline for Good Clinical Practice 
(GCP) defines an AE as “any untoward medical occurrence in a patient or clinical investigation 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
49 subject administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment. An adverse event (AE) can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product .”  
8.1.3  Serious Adverse Events 
A serious adverse event (SAE) is one that meets one or more of the following criteria: 
• Results in death  
• Is life -threatening (places the participant  at immediate risk of death from the event as it 
occurred)  
• Results in inpatient hospitalization or prolongation  of existing hospitalization 
• Results in a persistent or significant disability or incapacity  
• Results in a congenital anomaly or birth defect  
• An important medical event that may not result in death, be life- threatening, or require 
hospitalization may be considered an SAE when, based upon appropriate medical 
judgment, the event may jeopardize the participant  and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. 
8.2 Time Period and Frequency for Event Assessment  and 
Follow -Up 
Unanticipated problems will be recorded in the data collection system throughout  the study.  
The PI will record all reportable events with start dates occurring any time after informed 
consent is obtained until 7 (for nonserious AEs) or 30 days ( for SAEs) after the last day of study 
participation. At each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome information until the event returns to baseline,  resolves , or stabilizes . If the AE does not meet these outcomes within 30 days after 
discontinuation or the end of the study, the participant  will be referred to an appropriate 
practitioner for continued care. 
8.3 Characteristics of Adverse Events  
8.3.1  Relationship to Stud y Drug  
The PI will make the determination of  the relation ship of an AE to the study drug according to 
the following guidelines : 
1. Related (Possible, Probable, Definite)  
a. The event is known to occur with the study intervention.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
50 b. There is a temporal relationship between the intervention and event onset.  
c. The event abates when the intervention is discontinued.  
d. The event reappears upon a re- challenge with the intervention.  
2. Not Related (Unlikely, Not Related)  
a. There is no temporal relationship between the intervention and event onset.  
b. An alternate etiology has been established. 
8.3.2  Relationship to Study Procedures  
The same procedure as described in Section 8.3.1  for determining the relatedness of an AE to 
study drug will be used to determine its relatedness to a study procedure.  
8.3.3  Expectedness of AEs 
The NIDCR Medical Monitor and the Study PI will be responsible for determining whether an AE 
is expected or unexpected. An AE  will b e considered unexpected if the nature, severity, or 
frequency of the event is not consistent with the risk information desc ribed in the protocol or the 
Investigator’s Brochure or discussed with the participant  during the informed consent process.  
8.3.4  Severity  of Event  
Adverse events will be graded on a scale from 1 to 5 according to the following standards from 
the National Cancer Institute‘s Common Terminology Criteria for Adverse Events  (v 4.0), which 
may be found in its entirety at http://ctep.cancer.gov/reporting/ctc.html : 
• Grade 1 = mild AE 
• Grade 2 = moderate AE 
• Grade 3 = severe or medically significant AE  
• Grade 4 = life -threatening AE 
• Grade 5 = death  
8.4 Reporting Procedures  
8.4.1  Adverse Event Reporting to I RB and NIDCR 
Study staff will report AEs on a case report form in the EDC system. Adverse events will be 
reported to the IRBs and DSMB according to guidelines established by those boards.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
51 8.4.2  Unanticipated Problem Reporting to IRB and NIDCR  
Incidents or events  that meet the OHRP criteria for unanticipated problems require the creation 
and completion of an unanticipated problem report form  within the EDC system . If an 
unanticipated problem also meets the criteria for an AE or SAE, it will be reported as an 
unant icipated problem and an AE or SAE. The OHRP recommends that investigators include 
the following information when reporting an adverse event, or any other incident, experience, or 
outcome as an unanticipated problem to the IRB:  
• Appropriate identifying information for the research protocol, such as the title, 
investigator’s name, and the IRB project number  
• A detailed description of the adverse event, incident, experience, or outcome  
• An explanation of the basis for determining that the adverse event, incident, experience, 
or outcome represents an unanticipated problem  
• A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the unanticipated problem  
To satisfy the requirement for prompt reporting, unanticipated problems will be reported using 
the following timeline:   
• Unanticipated problems that are SAEs  will be reported to the IRB and to NIDCR within 
1 week of the investigator becoming aware of the event.  
• Any other UP  will be reported t o the IRB and to NIDCR within 2  weeks of the investigator 
becoming aware of the problem.  
• All UPs  should be reported to appropriate institutional officials (as required by an 
institution’s written reporting procedures), the supporting agency head (or desig nee), 
and OHRP within one month of the IRB’s receipt of the report of the problem from the 
investigator.  
All unanticipated problems will be submitted on the UP form within the EDC  system to NIDCR’s 
centralized reporting system via Rho Product Safety. However, in cases when the EDC system 
is not available, the investigator may report the UP by fax or email : 
• Product Safety Fax Line (US):  1-888-746-3293  
• Product Safety Email:  rho_productsafety@rhoworld.com   
General questions about UP reporting can be directed to the Rho Product Safety Help Line 
(available 8:00AM – 5:00PM Eastern Time):   
• US: 1 -888-746-7231  
8.4.3  Serious Adverse Event Reporting to NIDCR  
Any AE meet ing the specified serious adverse event criteria will be submitted on an SAE f orm 
within the EDC system to NIDCR’s centralized safety system via Rho Product Safety . However, 
in cases when the EDC system is not available, the investigator may report the SAE by fax or email. Once submitted, Rho Product Saf ety will send a confirmation email to the investigator 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
52 within 1 business day. The investigator should contact Rho Product Safety if this confirmation is 
not received. This process applies to both initial and follow -up SAE report s.  
SAE Reporting Contact In formation:    
• Product Safety Fax Line (US):  1- 888-746-3293  
• Product Safety Email:  rho_productsafety@rhoworld.com   
General questions about SAE reporting can be directed to the Rho Product Safety Help Line (available 8:00AM – 5:00PM Eastern Time):   
• US: 1 -888-746-7231  
The study clinician will complete a Serious Adverse Event Form and submit within the EDC 
system (or via fax or email if the EDC system is not available) within the following timelines:   
• All deaths and immediately life- threatening events, whether related or unrelated to the 
study drug , will be recorded on the Serious Adverse Event Form and submitted to 
Product Safety wi thin 24 hours of site awareness.   
• Serious adverse events other than death and immediately life-threatening events, 
regardless of relationship to the study drug , will be reported within 72 hours of site 
awareness .  
All SAEs will be followed until resolution or stabilization.  
Serious adverse events will be reported to the IRBs and DSMB according to guidelines 
established by those boards.  
8.4.4  Reporting Abnormal Clinical Findings  
Any clinically significant worsening of a medical condition (other than TMD) established at baseline or the development of any new clinically significant medical  condition during the study 
will be considered an AE and will be reported as described previously.  
8.4.5  Reporting of Pregnancy  
Pregnancy will be recorded on a case report form within the EDC system if it begins any time 
during the study. Pregnancy will not be regarded as an SAE unless there is suspicion that the  
study drug may have interfered with the effectiveness of a contraceptive medication and the 
event meets the criteria for an unanticipated problem. Results of all positive pregnancy tests will 
be given to the participant and/or her legally authorized representative, as appropriate.  
Participants who become pregnant while participating in the study will be discontinued from the study and referred for appropriate care. If a participant becomes pregnant while receiving the 
study drug, she will be followed for safety until a pregnancy outcome is reached. If the 
pregnancy results in an outcome other than a normal birth or elective abortion of a healthy fetus, it will be reported as an SAE.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
53 8.5 Halting Rules  
See Secti on 4.4.6 , Suspension or Termination of the Study.  
9 STUDY O VERSIGHT  
In addition to the PI’s responsibility for oversight, s afety  oversight will b e under the direction of a 
DSMB  convened by NIDCR . The DSMB is composed of members with expertise in pain 
management. The DSMB will meet periodically  or as needed to assess safety and effi cacy data , 
study progress, and data integrity  for the study. If safety concerns arise, more frequent meetings 
may be held. The D SMB will operate under the rules of an NIDCR- approved charter that will be 
written at the organizational meeting of the DSMB. At this time, most data elements that the 
DSMB needs to assess will be clearly defined. The DSMB will provide recommendations to the 
NIDCR. The PI will be responsible for responding to inquir ies and recommendations made by 
the DSMB.  
10 CLINICAL MONITORING 
Clinical site monitoring is conducted to ensure that the rights of human participants  are 
protected, that the study is implemented in accordance with the protocol and/or other operating procedures, and that the quality and integrity of study data and data collection methods are maintained.  Monitoring for  this study will be performed by NIDCR’s Clinical Research 
Operations and Management Support (CROMS) contractor. The monitor will evaluate study processes and documentation based on NIDCR standards and the ICH E6: GCP guidelines.  
Details of clinical site m onitoring will be documented in a Clinical Monitoring Plan (CMP) 
developed by the CROMS contractor, in collaboration with the NIDCR Office of Clinical Trials and Operations Management (OCTOM) and the NIDCR Program Official. The CMP will specify 
the frequency of monitoring, monitoring procedures, the level of clinical site monitoring activities 
(e.g., the percentage of participant  data to be reviewed), and the distribution of monitoring 
reports. Some monitoring activities may be performed remotely, while others will take place at 
the study site(s). Staff from the CROMS contractor will conduct monitoring activities and provide 
reports of the findings and associated action items in accordance with the details described in the CMP. Documentation of monitoring activities and findings will be provided to the site study 
team, the study PIs, OCTOM, and the NIDCR. The NIDCR reserves the right to conduct 
independent audits as necessary. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
54 11 STATISTICAL CONSIDER ATIONS  
11.1 Study Hypotheses  
11.1.1  Primary Hypothesis  
We hypothesize that among this study population of participant s with TMD, the net change in 
the mean pain index at Visit 4 will be greater in the propranolol -treated arm than in the placebo-
treated arm.  Net change is defined as the difference between the participant's mean pain index 
at Visit 1 and each subsequent visit. Efficacy of propranolol is defined as the difference between 
the propranolol and placebo arms in the mean net change. Figure 2 uses hypothetical data to 
illustrate how the primary hypothesis is restricted to efficacy at Visit 4 ( ∆V4). 
Figure 2. Hypothetical D ata Illustrating the Primary Hypothesis  
 
11.1.2  Secondary Hypothesis  
• We hypothesize that among this study population of participant s with TMD, the efficacy 
of propranolol will vary according to the number of  LPS haplotypes of the COMT  gene. 
• We hypothesize that, compared with participant s in the placebo -treated arm, participant s 
in the propranolol- treated arm will have more favorable secondary endpoints, namely: 
(1) reduction in additional ratings of pain; (2 ) reduction in examiner -assessed levels of 0 1 2 3 4 5 6 7 8 9-30-20-100
Placebo
Active∆V4
V1 V2 V3 V4
Weeks of treatmentNet change in pain index
compared to V1
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
55 pain sensitivity (pressure and heat pain sensitivity) ; (3) better participant ratings of 
physical function,  emotional function, and global improvement ; and (4) less frequent use 
of rescue medications  and over -the-counter medications for pain .  
11.1.3  Exploratory Hypotheses  
• We hypothesize that efficacy of propranolol will vary according to genetic variants  
including, but not limited to the COMT  gene promoter  and the ADRB2  and ADRB3  
genes.  
• We hypothesize that efficacy of propranolol will vary according to phenotypic 
characteristics. 
11.2 Sample Size Considerations  
This study plans to randomize 200 participant s, which will  provide 94% power  (alpha = 0. 05) to 
detect a difference between a 27% reduction in pain index in the propranolol arm and a 
9% reduction in the placebo arm (primary hypothesis) . Assuming haplotype distributions and 
within -haplotype treatment effects that are similar to those observed in the pilot study, the same 
sample size would provide 61%  power (alpha = 0.05) to detect an interaction between 
haplotype and treatment group ( secondary hypothesis ). The assumptions for these power 
calculations are shown in the following table. Power calculations were made using the 
GLMPOWER procedure in SAS, which assumes a data structure of one observation per person. 
This is a simplification of the situation that will occur with the linear mixed model described in 
Section 11.4.1 in which  efficacy will be evaluated using a data structure in which  most 
participants will have three observations per person. The simplified power calculations are 
shown here because conventional software for power calculations does not deal with the more complex situation of linear mixed models.  
 Primary 
Hypothesis   Secondary  
Hypothesis  
COMT  haplotype  All haplotypes   0 LPS copies   1 LPS copy   2 LPS copies  
Treatment arm  Drug  Placebo   Drug  Placebo   Drug  Placebo   Drug  Placebo  
% of participant s (N = 200)  50% 50%  15% 15%  25% 25%  10% 10% 
Mean baseline p ain index  3000  3000   3000  3000   3000  3000   3000  3000  
Net change  -810 -270  -1350  -270  -810 -270  -270 -270 
Percent age change  -27 -9  -45 -9  -27 -9  -9 -9 
∗ LPS stands for low pain sensitive, one of the major haplotypes of COMT . The s tandard deviation for the mean 
baseline pain index is  estimated to be 1190. The net change takes into account a 10% lost -to-follow -up rate and 
imputation using the last  observation carried forward approach.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
56 11.3 Analysis Samples  
11.3.1  Intention- To-T reat Sample  
Consistent with the primary statistical method that will use a linear mixed model (also called 
"mixed model repeated measures" model), the intent ion-to-treat sample is defined as all study 
participants who have at least one valid measurement of the primary endpoint at V isit 2 or later. 
A "valid" assessment for the primary endpoint is de fined as at least 4  daily reports of pain 
intensity and duration collected in the 7 -day period prior to the visit  (Section 2.5.1 ). Treatment 
group allocation will be defined as the study arm into which the subject was randomized 
regardless of the actual study treatment received.  By necessity, the intention- to-treat sa mple 
excludes participants who provide no data for the primary endpoint after randomization. Note that follow -up assessments will be included in the intention- to-treat analysis when sufficient 
diary data are collected at the follow -up assessment, even if there were protocol violations. 
Likewise, the intention- to-treat sample will include all available follow -up assessments from any 
discontinued participants.  
11.3.2  Per-Protocol Sample  
Secondary statistical analysis of the primary hypothesis will be in the spirit o f per-protocol 
analysis.  The per -protocol sample will be a subset of the intention- to-treat sample, excluding 
any assessments made at or after a visit at which the participant is found to have any protocol 
deviation listed in Section 5.8. In addition, all assessments for participants whose compliance 
with study medication is less than 60% over all study visits will be excluded from per- protocol 
analyses.  
11.3.3  Safety Sample 
The safety sample will include  all randomized participant s who received at  least one dose of 
study medication. Participant s in the safety sample will be analyzed with the treatment group 
according to the medication they actually rec eived,  regardless of their randomized assignment.  
11.4 Analyses 
Complete details of all statistical analyses will be provided in the Statistical Analysis Plan, which 
will be completed prior to database lock and analysis. Below is an overview of the analyses for  
the primary and secondary hypotheses. 
11.4.1  Analysis of the Primary Hypothesis  
The primary statistical analysis to evaluate the primary hypothesis will use all data from the 
intention- to-treat analytic al sample in a linear mixed model.  During the analysis  of the primary 
hypothesis , treatment allocation will be masked (i.e., groups will be labeled A and B). Treatment 
allocation will be unmasked for further analys es. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
57 The dependent variable will be the participant's change in the weekly pain index, computed as 
the weekly pain index at the follow -up visit (i.e., at Visit 2, Visit 3, or Visit 4) minus the Visit 1 
weekly pain index. Explanatory variables will comprise fixed factors and a continuous c ovariate. 
The f ixed factors will include the following: (a) treatment allocation ( two categories ) (b) visit 
sequence (three categories ); (c) interaction of treatment allocation and visit sequence (two 
dummy variables) ; and (d) covariates of study site ( three categories ), sex (two categories) and 
race/ethnicity (probably three categories: non -Hispanic White, non -Hispanic Black, and 
other/multiple racial or ethnic groups – the final number of conditions will be dictated by the 
frequency distribution of race/ethnicity  in the study sample) . The baseline score collected at Visit 
1 will be the continuous covariate, modeled as a fixed effect  The study participant will be 
modeled as a random factor.  
In a linear mixed model containing all predictor variables including the interaction terms  for visit 
and treatment allocation, the primary treatment effect will be tested at V isit 4. The null 
hypothesis of no treatment effect will be rejected if the P- value at Visit 4  is ≤ 0.05. For 
descriptive purposes (and regardless of the P -value for efficacy at Visit  4), efficacy estimate s at 
each visit (2, 3 and 4)  will be described in terms of adjusted means and 95 % confidence 
intervals . 
If the propranolol treatment arm has a greater reduction in the weekly pain index than the placebo arm at Visit 4 , a threshold of "responder analysis" will be underta ken to estimate the 
odds of at least a 30% reduction, relative to Visit 1, in the pain index  at Visit 4. Likewise, another 
threshold of responder analysis will describe the odds of experiencing at least a 50% reduction. 
These estimates will be calculated from a logistic model in which the dependent variable is a 
binary variable that  dichotomizes the change score at the appropriate threshold (i.e., ≥  30% or ≥  
50%).  
Secondary analyses of the primary hypothesi s will be conducted as  described above, but using 
the per-protocol  sample.  
Stratified analysis in the intention- to-treat sample will estimate treatment effects separately for 
the two sexes and for the main racial- ethnic groups. The analysis will be descriptive, reporting 
means and 95% confidence intervals. There will be no hypothesis tests of efficacy within 
demographic subgroups because of the expected small numbers of males and minorities.  
11.4.2  Analysis of the Secondary Hypotheses  
To test the secondary hypothesis of gene -by-treatment  interaction, t he linear mixed model 
described for the primary analysis will  be extended by adding three sets of predictor variables: 
(1) the number of COMT LPS haplotypes (0, 1 , or 2) will be modeled as a fixed effect , either as 
a continuous variable, or as a 3- level categorical variable (i.e., two dummy variables), with the 
decision based on the approach that optimizes model fit, as determine by Akaike ’s Information 
Criterion ; (2) two -way interactions between haplotype effect and treatment allocation and 
between haplotype effect and visit sequence ; and (3) a three -way interaction term between the  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
58 haplotype effect , treatment  allocation, and visit  sequence . The gene- by-treatment interaction at 
V4 is the interaction of  interest.   
For descriptive purposes, an analogous model will generate efficacy estimates according to 
COMT  Val158Met genotype as the genetic marker instead of the number of LPS haplotype. In an 
analogous manner, the genotype will be coded either as a continuous or categorical variable 
based on optimal model fit.  Efficacy estimates will be calculated for descriptive purposes only; 
there will be no hypothesis tests for the interaction terms.   
Another descriptive  set of secondary analyses will adapt the approach for analys is of the LPS 
haplotype, restricting the  model to non -Hispanic whites. This is consistent with the approach of 
some genetic researchers who advocate racial -group restriction as a preferable analytic method 
to control for population stratification. 
Linear mixed models will be used to evaluate effects of treatment group allocation on secondary  
efficacy variables (see S tatistical Analysis Plan for full details ). 
Linear regression or other appropriate statistical model ing will evaluate the effects of tr eatment 
on the number of days in which  rescue medications for TMD -related pain  reportedly were used 
and on the number of days in which over -the-counter analgesics ( namely, NSAIDs, 
acetaminophen, and aspirin) reportedly were used for treatment of any type o f pain.  
See the Statistical Analysis Plan for more details on these secondary analyses.   
11.4.3  Analysis of the Exploratory Hypotheses  
The exploratory hypotheses will extend  the analy tical procedures described above. In summary:  
• The linear mixed model described for the secondary hypothesis will be modified by 
specifying genetic variants including, but not limited to the COMT  gene promoter  and the 
ADRB2  and ADRB3  gene s. 
• Other phenotypes will be evaluated as potential treatment effect modifiers using a similar strategy in which linear mixed models will test for phenotype- by-treatment interactions.  
Each phenotype will be categorized based on characteristics assessed either  at V0 or 
V1. The phenotypes are: body mass index; smoking; migraine headache;  tenderness to 
body palpation; catastrophizing subscale of the CSQ -R questionnaire; s elf-rated general 
health from the SF- 12v2 questionnaire; anxiety and depression subscales fr om the 
HADS questionnaire; sleep quality from the PSQI questionnaire; and s ubjects’ rating of 
confidence in treatment outcome .  Full details are provided in  the Statistical Analysis 
Plan.  
The exploratory analysis will further explore the results, insights,  or new questions that may 
arise during the study’s analyses and will not be limited to the exploratory analyses listed above.  
11.5 Planned Interim Analyses  
No interim analyses are planned.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
59 12 SOURCE DOCUMENTS AND  ACCESS TO SOURCE 
DATA AND DOCUMENTS 
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Examples 
of these original documents and data records include, but are not limited  to, hospital records, 
clinical and office charts , laboratory notes, memoranda, participant s’ memory aid or evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, recorded 
audio tapes of counseling sessions, copies or  transcriptions certified after verification as being 
accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, 
x-rays, and participant  files and records kept at the pharmacy, at the laboratories, and 
medico- technical departments involved in the clinical trial.  It is acceptable to  use case report 
forms  as source documents. For this study, some clinical examination and questionnaire  data 
may be recorded directly from the participant  onto the Teleform case report forms  (paper) , with 
the case report form being the source document.  
Each clinical site will maintain appropriate medical and research records for this trial in 
compliance with Section 4.9 of ICH E6 and regulatory and institutional requirements for the 
protection of confi dentiality  of participant s. As part of participating in an NIDCR- funded  study, 
each site will permit authorized representatives of the NIDCR, including CROMS clinical 
monitors, and regulatory agencies to examine (and when required by applicable law, to copy) 
clinical records for the purposes of quality assurance reviews, audits, and evaluation of the study ’s safety and progress.  
13 QUALITY CONTROL AND QUALITY ASSURANCE  
Quality control is the ongoing, concurrent review of data collection forms for completion and 
logic. Quality assurance is a comprehensive, retrospective review of all components of research 
records to assess adherence to protocol, standard operation procedures, and regulations and to 
evaluat e the accuracy of the records. Quality management is the process of assessing the 
quality of processes within a system and encompasses quality assurance and quality control.  
The quality management program will include, but will not be limited to, the following:  
• A study start -up list of tasks that must be completed and approved by the NIDCR 
program  officer prior to the first participant  visit 
• Training of staff on the protocol, study procedures, and use of the data collection forms 
and systems  
• Documentation and tracking of training for each staff member  
• A Clinical Monitoring Plan that describes p eriodic clinic  visits by monitors to ensure that  
the rights of human participant s are protected, the study is implemented in accordance 
with the protocol, and the integrity of study data is maintained 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
60 • A Data Management Plan that describes  procedures for data entry  and completion, data 
security, and data  quality control and validation 
14 PROTECTION OF HUMAN PARTICIPANTS 
14.1 Institutional Review Board  
Each participating institution will provide for the review and approval of this protocol and the 
associated informed consent documents and recruitment material s by an appropriate IRB 
registered with the OHRP . Any amendments to the protocol or consent materials will also be 
approved by the IRB before they are placed int o use. 
14.2 Informed Consent Process  
Written documentation of informed consent will be  obtained prior to an individual’s participation 
in the study . An IRB-approved consent form describing in detail the study interventions, 
procedures, and risks will  be given to the participant . The participant  will be asked to read and 
review the document, and upon reviewing the document, the investigator  or designee will 
explain the research study to the participant  and answer any questions that may arise. The 
participant  will have the opportunity to discuss the study with others, such as family members,  
or to take additional time before agreeing to participate. A participant  may withdraw consent at 
any time throughout the course of the trial.  A copy of the informed consent document will be 
given to the participant  for her records.  
14.3 Exclusion of Special Populations  
This protocol does not exclude any special populations.  
14.4 Participant  Confidentiality  
Participant  confidentiality will be  strictly held in trust by the participat ing investigators, their staff, 
the data coordinating center, and the NIDCR and its agents. This confidentiality will be  extended 
to cover testing of biological samples and genetic tests in addition to the clinical information 
relating to study  participant s. 
The study protocol, documentation, data, and all other information generated will be held in strict confidence.  No information concerning the study or the data will be released to any 
unauthorized third party without prior written approval of the NIDCR program official. 
The clinical monitor or other authorized representatives of the NIDCR may inspect all 
documents and records required to be maintained by the investigator, including but not limited to medical records (office, clinic, or hospital) and phar macy records for the participant s in this 
study.  The clinical study site will permit access to such records.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
61 Research information about the participants will be collected on either paper or electronic forms 
that will contain a study identification number rather than a name or any other information that 
could be used to identify the participant. Only the study staff will have access to the lis t that links 
the name and identification number. All paper research forms will be kept under lock and key.  
14.5 Future Use of Stored Specimens  
Biological specim ens will be stored indefinitely at one or both of the clinical sites for participant s 
who provide consent. The consent form will allow participant s to choose whether to have their 
samples stored indefinitely for future analyses . Any new use of study specimens, i.e., uses not 
described in this protocol,  will require IRB review and approval. Stored s pecimens will be 
identifi able by participant  identification number. The link between the participant ’s name and the 
identification number will be maintained and stored confidentially by the study investigators. Any 
loss or unintentional destruction of the samples  will be reported to the IRB s. If it is determined 
that no additional investigations are planned on the study specimens, the  specimens  will be 
disposed of in accordance with environmental protection laws, local regulations, and guidelines of the US federal  government.  
The consent for future use of specimens will include the possibility that genetic information may be obtained from the specimens and shared with other researchers via an NIH database. In accordance with the NIH Genomic Data Sharing Policy, an IRB will need to ensure that data 
submission is consistent with the informed consent provided by the research participant.   
14.6 Data Handling and Record Keeping  
All source documents will  be completed in a neat, legible manner to ensure ac curate 
interpretation of data. Black or blue ink is required to ensure clarity of reproduced copies.  When 
making corrections, t he original entry will be crossed out with a single line, and the correction 
will be initialed and date d. No entries will be erased or overwritten. Data reported on case report 
forms  will be consistent with the source documents or the discrepancies will be explained and 
documented. For this study, case report forms (paper or electronic) may serve as the source 
document for the collection of some types  of data, such as questionnaire data or clinical 
examination findings.  
14.7 Data Management Responsibilities  
The investigator will ensure  the accuracy, completeness, legibility, and timeliness of the data 
collection . During the study, the investigator will main tain complete and accurate documentation 
for the study.  All source documents and laboratory reports will be reviewed by the clinical team 
and data entry staff, who will ensure that all recorded information is  accurate and complete. The 
data coordinating center  will be r esponsible for data management, data quality review, and data 
analys es. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
62 14.8 Data Capture Methods  
Study staff will complete c ase report forms online via a web- based EDC system that has been 
validated and is compliant with Title 21 CFR  Part 11. T he data will be stored remotely at a 
central database managed by the data coordinating center. Data quality will be ensured through 
the data collection system’s continuous monitoring of data and real -time detection and 
correction of errors.  All elements of data entry (i.e., time, date, verbatim text, and the name of 
the person performing the data entry) will be recorded in an electronic audit trail to allow all 
changes in the database to be monitored and maintained in accordance with federal 
regulations.  
14.9 Type s of Data  
Clinical examination findings, clinical test results, demographic and medical history data, outcome measures obtained from questionnaires, and genetic data will be collected in this 
study.  
14.10  Timing of Reports  
The data coordinating center will post s tudy progress reports (i.e., screening, enrollment, and 
study progress reports) to the study website periodically throughout the study period, as 
determined by the NIDCR program official and the PI . The data coordi nating center will also 
post data managem ent reports that contain measures of data quality , such as the numb er of 
outstanding data queries  and data completion rates . Study reports will be provided to the DSMB 
and IRB s prior to their periodic meetings . No interim statistical analyses  are planned. 
14.11  Study Records Retention 
Records will be maintained for at least 3 years from the date that the final financial status report 
is submitted to the NIH. No records will be destroyed without the written consent of the NIH.  
14.12  Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or the MOP. The 
noncompliance may be on the part of the participant , the investigator, or the study site staff.  All 
protocol deviations will be promptly  reported within the EDC system and to t he NIDCR program 
official. Protocol deviations will also be reported to the IRBs and the DSMB according to their 
guidelines.  As a result of deviations, corrective actions will be developed by the site(s) and 
implemented promptly.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
63 15 PUBLICATION/D ATA SHARING  POLICY  
This study will comply with the NIH Public Access Policy , which ensures that the public has 
access to the published results of NIH -funded research. It requires scientists to submit final 
peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed 
Central  upon acceptance for publication.  
This study will comply with the NIH Data Sharing Policy, which ensures that data are as widely 
and freely available as possible while safeguarding the privacy of participants, and protecting 
confidential and proprietary data. Genetic and non- genetic data  collected in this study will be 
stored for use by other researchers. Datasets will not contain any personal identifying 
information, and an IRB will need to determine whether the  data may be released to 
researchers.  
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted 
a clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial 
as any research project that prospectively assigns human participants  to intervention or 
concurrent comparison or control groups to study the cause -and-effect relationship between a 
medical intervention and a health outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process -of-care changes, and the like. Health 
outcomes include any biomedical or health- related measures obtained in patients or 
participants , including pharmacokinetic measures and AEs. The ICMJE policy requires that all 
clinical trials be registered in a public trials registry such as ClinicalTrials.gov
, which is 
sponsored by the National Library of Medicine. Other biomedical journals are considering 
adopting similar policies. For interventional clinical trials performed under NIDCR grants and 
cooperative agreements, it is the grantee’s responsibility to register the trial in an acceptable registry, so the research results may be considered for publication in ICMJE member journals.  
The ICMJE does not review specific studies to determine whether registration is necessary ; 
instead, the committee recommends that researchers who have questions about the need to register err on the side of registration or consult the editorial office of the journal in which they 
wish to publish.  
U.S. Public Law 110- 85 (Food and Drug Administration Amendments Act of 2007 or FDAAA), 
Title VIII, Section 801 mandates that a "responsible party" (i.e., the sponsor or designated principal investigator) register and report results of certain "applicable clinical trials:"  
Trials of Drugs and Biologics:  Controlled, clinical investigations, other than Phase I 
investigations, of a product subject to FDA regulation;  
Trials of Devices: Controlled trials with health outcomes of a product subject to FDA regulation 
(other than small feasibility studies) and pediatric post market  surveillance studies.  
NIH grantees must take specific steps to ensure compliance with NIH implementation of 
FDAAA.   
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
64 16 LITERATURE REFERENCES 
1. De Leeuw R, editor. Orofacial pain: guidelines for assessment, diagnosis, and 
management. 4th ed. Chicago: Quintessence Publishing Co, Inc; 2008. 
2. Machado LP, Nery Cde G, Leles CR, Nery MB, Okeson JP. The prevalence of clinical 
diagnostic groups in patients with temporomandibular disorders. Cranio. 2009;27(3):194 -9. 
3. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: 
review, criteria, examinations and specifications, critique. J Craniomandib Disord. 
1992;6(4):301 -55. 
4. Dworkin SF, Huggins KH, LeResche L, Von Korff M, Howard J, Truelove E, Sommers E. 
Epidemiology of signs and symptoms in temporomandibular disorders: clinical signs in cases 
and controls. J Am Dent Assoc. 1990;120(3):273- 81. 
5. Dworkin SF, LeResche L. Temporomandibular disorder pain: Epidemiologic data. APS 
Bulletin. 1993;April/May:12.  
6. Dahlstrom L, Carlsson GE. Temporomandibular disorders and oral health- related quality 
of life. A systematic review. Acta Odontol Scand.68(2):80- 5. 
7. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain. 
1992;50(2):133 -49. 
8. Chen H, Slade G, Lim PF, Miller V, Maixner W, Diatchenko L. Relationship between 
temporomandibular disorders, widespread palpation tenderness, and multiple pain conditions: a 
case- control study. J Pain. 2012;13(10):1016 -27. 
9. Plesh O, Adams SH, Gansky SA. Temporomandibular joint and muscle disorder -type 
pain and comorbid pains in a national US sample. J Orofac Pain. 2011;25(3):190 -8. 
10. Hersh EV, Balasubramaniam R, Pinto A. Pharmacologic management of 
temporomandibular disorders. Oral Maxillofac Surg Clin North Am. 2008;20(2):197- 210, vi. 
11. List T, Axelsson S. Management of TMD: evidence from systematic reviews and meta -
analyses. J Oral Rehabil. 2010;37(6):430- 51. 
12. Evaskus DS, Laskin DM. A biochemical measure of stress in patients with myofascial 
pain- dysfunction syndrome. J Dent Res. 1972;51(5):1464- 6. 
13. Perry F, Heller PH, Kamiya J, Levine JD. Altered autonomic function in patients with 
arthritis or with chronic myofascial pain. Pain. 1989;39(1):77 -84. 
14. Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL, Chrousos GP, Pillemer  SR. 
Responses of the sympathetic nervous system and the hypothalamic -pituitary -adrenal axis to 
interleukin -6: a pilot study in fibromyalgia. Arthritis Rheum. 2000;43(4):872- 80. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
65 15. Khasar SG, McCarter G, Levine JD. Epinephrine produces a beta- adrenergic r eceptor -
mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J Neurophysiol. 
1999;81(3):1104 -12. 
16. Light KC, Bragdon EE, Grewen KM, Brownley KA, Girdler SS, Maixner W. Adrenergic 
dysregulation and pain with and without acute beta -blockade in women with fibromyalgia and 
temporomandibular disorder. J Pain. 2009;10(5):542- 52. 
17. Wood PB, Kablinger AS, Caldito GS. Open trial of pindolol in the treatment of 
fibromyalgia. Ann Pharmacother. 2005;39(11):1812- 6. 
18. Rodrigues LL, Oliveira MC, Pelegrini -da-Silva A, de Arruda Veiga MC, Parada CA, 
Tambeli CH. Peripheral sympathetic component of the temporomandibular joint inflammatory pain in rats. J Pain. 2006;7(12):929 -36. 
19. Keller S, Frishman WH. Neuropsychiatric effects of cardiovascular drug therapy. Cardiol 
Rev. 2003;11(2):73 -93. 
20. Tchivileva IE, Lim PF, Smith SB, Slade GD, Diatchenko L, McLean SA, Maixner W. 
Effect of catechol -O-methyltransferase polymorphism on response to propranolol therapy in 
chronic musculoskeletal pain: a randomized, double- blind, placebo- controlled, crossover pilot 
study. Pharmacogenet Genomics. 2010;20(4):239 -48. 
21. Mannisto PT, Kaakkola S. Catechol -O-methyltransferase (COMT): biochemistry, 
molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999;51(4):593- 628. 
22. Marbach JJ, Levitt M. Erythrocyte catechol-O- methyltransferase activity in facial pain 
patients. J Dent Res. 1976;55(4):711.  
23. Nackley AG, Shabalina SA, Chivileva IE, Satterfield KS, Korchynskyy O, Maixner W, 
Diatchenko L, editors. Common human catechol -O-methyltransferase haplotypes modulate 
RNA stability, protein expression, and enzymatic activity. American Society for Human 
Genetics; 2005; Salt Lake City, Utah.  
24. Lotta T, Vidgren J, Ti lgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J. Kinetics of 
human soluble and membrane- bound catechol O -methyltransferase: a revised mechanism and 
description of the thermolabile variant of the enzyme. Biochemistry. 1995;34(13):4202- 10. 
25. Gursoy S,  Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N. Significance of catechol -
O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int. 
2003;23(3):104 -7. 
26. Erdal ME, Herken H, Yilmaz M, Bayazit YA. Significance of the catechol -O-
methyltransferase gene polymorphism in migraine. Brain Res Mol Brain Res. 2001;94(1 -2):193-
6. 
27. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, 
Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W. Genetic basis for individual 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
66 variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 
2005;14(1):135 -43. 
28. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, 
Goldman D. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain 
stressor. Science. 2003;299(5610):1240- 3. 
29. Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE, Skorpen F. 
The Val158Met polymorphism of the human catechol -O-methyltransferase (COMT) gene may  
influence morphine requirements in cancer pain patients. Pain. 2005;116(1 -2):73- 8. 
30. Diatchenko L, Nackley AG, Slade GD, Bhalang K, Belfer I, Max MB, Goldman D, 
Maixner W. Catechol -O-methyltransferase gene polymorphisms are associated with multiple 
pain- evoking stimuli. Pain. 2006;125(3):216 -24. 
31. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, 
Maixner W, Diatchenko L. Human catechol-O- methyltransferase haplotypes modulate protein 
expression by altering mRNA secondary  structure. Science. 2006;314(5807):1930 -3. 
32. Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W. Catechol -O-
methyltransferase inhibition increases pain sensitivity through activation of both beta2- and 
beta3- adrenergic receptors. Pain. 2007;128(3):199- 208. 
33. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, 
Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, 
Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermot t MP, McGrath P, 
Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer 
JW, Stein W, Tollett J, Wernicke J, Witter J. Core outcome measures for chronic pain clinical 
trials: IMMPACT recommendations. Pain. 2005;113(1- 2):9-19. 
34. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for 
reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726- 32. 
35. Manfredini D, Arveda N, Guarda -Nardini L, Segu M, Collesano V. Distribution of 
diagnoses  in a population of patients with temporomandibular disorders. Oral Surg Oral Med 
Oral Pathol Oral Radiol . 2012;114(5):e35 -41. 
36. Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet J -P, List T, Svensson 
P, Gonzalez Y, Lobbezoo F, Michelotti A,  Brooks SL, Ceusters W, Drangsholt M, Ettlin D, Gaul 
C, Goldberg L, Haythornthwaite J, Hollender L, Jensen R, John MT, deLaat A, deLeeuw R, 
Maixner W, van der Meulen M, Murray GM, Nixdorf DR, Palla S, Petersson A, Pionchon P, 
Smith B, Visscher CM, Zakrzewska J, Dworkin SF. Diagnostic Criteria for Temporomandibular 
Disorders (DC/TMD) for Clinical and Research Applications: Recommendations of the 
International RDC/TMD Consortium Network and Orofacial Pain Special Interest Group. J Oral 
Facial Pain Headache. 2 014;28(1):6 -27. 
37. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell 
P, Campbell SM, Abeles M, Clark P, et al. The American College of Rheumatology 1990 Criteria 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________  
67 for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis 
Rheum. 1990;33(2):160- 72. 
38. Babor TF, Higgins -Biddle JC, Saunders JB, Monteiro MG. The Alcohol Use Disorders 
Identification Test Guidelines for Use in Primary Care, 2nd edition. WHO/MSD/MSB/01.6a, World Health Organization, Geneva, 2001. 
39. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 
1975;1(3):277 -99. 
40. Underwood MR, Barnett AG, Vickers MR. Evaluation of two time- specific back pain 
outcome measures. Spine (Phila Pa 1976). 1999;24(11):1104- 12. 
41. Ware J, Jr., Kosinski M, Keller SD. A 12 -Item Short -Form Health Survey: construction of 
scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220- 33. 
42. Guy W. ECDEU assessment manual for psychopharmacology. In: U.S. Department of 
Health EaW, editor. Rockville, MD1976. p. 217- 22. 
43. Ohrbach R, Granger C, List T, Dworkin S. Preliminary development and validation of the 
Jaw Functional Limitation Scale. Community Dent Oral Epidemiol. 2008;36(3):228- 36. 
44. Ohrbach R, Larsson P, List T. The jaw functional limitation scale: development, 
reliability, and validity of 8- item and 20 -item versions. J Orofac Pain. 2008;22(3):219 -30. 
45. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health 
Soc Beh av. 1983;24(4):385- 96. 
46. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr 
Scand. 1983;67(6):361 -70. 
47. Krogstad BS, Jokstad A, Dahl BL, Soboleva U. Somatic complaints, psychologic 
distress, and treatment outcome in two groups of TMD patients, one previously subjected to 
whiplash injury. J Orofac Pain. 1998;12(2):136 -44. 
48. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep 
Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 
1989;28(2):193 -213. 
49. Rosenstiel AK, Keefe FJ. The use of coping strategies in chronic low back pain patients: 
relationship to patient characteristics and current adjustment. Pain. 1983;17(1):33- 44. 
50. The International Classification of Headache Disorders, 3rd edition (beta version). 
Cephalalgia. 2013;33(9):629- 808. 
51. Kosinski M, Bayliss MS, Bjorner JB, Ware JE, Jr., Garber WH, Batenhorst A, Cady R, 
Dahlof CG, Dowson A, Tepper S. A six -item short -form survey for measuring headache impact: 
the HIT- 6. Qual Life Res. 2003;12(8):963- 74. 
 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 __________________________________________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________________________________  
68 APPENDIX A: SCHEDULE  OF EVENTS  
Study Phase: Pre-
screeninga Screening  
and 
Baseline  Randomization and Treatment  
(1 week titration,  8 weeks maintenance, and  
1 week taper ) Follow -Up 
Clinic Visit:   V0 V1b V2 V3 V4 V5 
                     Study Day : ≤ 28 days prior 
to V0 7 to 21 days 
prior to V 1  0 7 (+ 3) 35 (± 7) 63 (+ 6) 77 (+ 7) 
Procedure         
Contact Information  x       
Prescreening Interview Script  x       
Informed Consentc  x      
Eligibility Review  x x x     
AUDIT Questionnaire   x      
Smoking Questionnaire   x     x 
Alcohol Consumption per week    x x x x x 
Demographic Information   x      
Medical History  and Review  x x x x x x x 
Concomitant Medications   x x x x x x 
Concomitant Therapies   x x x x x x 
Dispense New Daily Symptom Diaries   x x x x x  
Adverse Event Review    x x x x x 
Collect Daily Symptom Diaries    x x x x x 
Assess Compliance with Daily Symptom 
Diaries    x x x x x 
Collect C onfidence in T reatment Outcome    x     
Randomization    x     
Dispense Study Drug    xd x x x  
Collect Study Drug Container(s)     x x x x 
Assess Compliance with Study Drug    x x x x 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 __________________________________________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________________________________  
69 Study Phase: Pre-
screeninga Screening  
and 
Baseline  Randomization and Treatment  
(1 week titration,  8 weeks maintenance, and  
1 week taper ) Follow -Up 
Clinic Visit:   V0 V1b V2 V3 V4 V5 
                     Study Day : ≤ 28 days prior 
to V0 7 to 21 days 
prior to V 1  0 7 (+ 3) 35 (± 7) 63 (+ 6) 77 (+ 7) 
Clinical Examinations and Tests         
Physical Measurements   x      
Vital Signs   x x x x x x 
Urine Pregnancy Test  (females)   x x x x x x 
Manual Tender Point Exam   x      
TMD Exam ination   x   x x  
Heat  and Pressure Pain Tests    x   x x  
12-Lead ECG   x      
Blood Draw    x   x  
Schedule Next Visit x x x x x x  
Outcome Measure Questionnaires         
Symptom Inventory   x x x x x x 
Fibromyalgia Questionnaire   x      
Headache Questionnairee   x     
SF-McGill Pain Questionnaire   x  x x x x 
Graded Chronic Pain Scalee   x  x x  
SF-12 Health Survey v2e   x  x x  
Jaw Functional Limitation Scalee   x  x x  
Perceived Stress Scalee   x  x x  
Hospital Anxiety and Depression Scalee   x  x x  
Pittsburgh Sleep Quality Indexe   x  x x  
Headache Impact Test (HIT -6) e   x  x x  
SCL-90R Somatization Scalee   x  x x  
Coping Strategies Questionnaire-Revisede   x     
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 __________________________________________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________________________________  
70 Study Phase: Pre-
screeninga Screening  
and 
Baseline  Randomization and Treatment  
(1 week titration,  8 weeks maintenance, and  
1 week taper ) Follow -Up 
Clinic Visit:   V0 V1b V2 V3 V4 V5 
                     Study Day : ≤ 28 days prior 
to V0 7 to 21 days 
prior to V 1  0 7 (+ 3) 35 (± 7) 63 (+ 6) 77 (+ 7) 
Patient Global Impression of Changee     x x  
AUDIT = Alcohol Use Disorders Identification Test; ECG = electrocardiogram; SCL -90 = Symptom Checklist -90R ; SF = Short Form; V = Visit  
a May occur by phone or at a clinic visit, and may be combined with the Screening and Baseline Visit (V isit 0). 
b If Visit 1 cannot occur within 3 weeks of Visit 0 and the participant  is to remain in the study, then Visit 0 will be repeated as an unscheduled visit . The timing of 
Visits 3 -6 and their windows are establis hed from the date of Visit 1. 
c Includes consent for study participation, consent to store biological specimens for future studies, and Health Insurance Portability and Accountability Act 
statement , if applicable . 
d The first dose of study drug should be taken in the evening of the Day 1 . 
e Questionnaires will be distributed at Visit 0 and the participant will return completed questionnaires at Visit 1.
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
71 APPENDIX B: PACKAGE INSERT FOR PROPRANOLOL HYDROCHL ORIDE  
EXTENDED -RELEASE  
  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
72 Propranolol hydrochloride exte nded- release capsules  
 
Rx only 
 
DESCRIP TION 
Propranolol hydrochloride is  a synthetic beta -adrenergi c recep tor-blocking agent chem ically 
described as 2-Propanol, 1- [(1-methylethyl)a mino]-3- (1-naphtha lenyloxy) -, hydrochloride,(±)-. 
Its molecular and struct ural for mulae are:  
 
 
C16H21NO2  · HCl 
 
Propranolol hydrochloride is  a stable,  white,  crystalline  solid  which  is readily  soluble in  water 
and ethanol. Its mol ecular  weight  is 295.80. 
 
Propranolol hydrochloride extended -release capsules  are formula ted to provide a sustained 
release of propranolol hydrochloride. Propranolo l hydrochloride extended -release capsules  are 
available as 60 mg, 80 mg, 120 mg, and 160 m g capsules for oral ad ministration.  
 The inactive  ingredients contained in propranolol hydrochloride ex tended -release capsules  are: 
cellulose, ethylcellulose, gelatin capsules, hypro mellose, and titanium dioxide. In addition, 
propranolol hydrochloride extended -release capsules  60 mg, 80 mg, and 120 mg capsules contain 
D&C Re d No . 28 an d FD& C Blu e No . 1; propranolol hydrochloride extended- release capsules 
160 mg capsules contain FD&C Blue No. 1.  These capsules co mply with USP Dissolution Test 1. 
 
CLINICA L PHARMACOLOGY  
General  
Propranolol is  a nonselective, beta- adrenergic receptor -blocking agent possessing no other 
autonom ic nervous system activity. It specific ally co mpetes with beta -adrenergic receptor - 
stimulating  agents  for availab le receptor  sites.  When access to  beta- recep tor sites  is blocked  by 
propranolol, the chronotropic, inotropic, and vasodila tor responses to be ta-adren ergic s timulation 
are decreased proportionately. At  dosages greater  than  required  for beta blockade, propranolol 
also exert s a quinidine -like or anesthetic- like m embrane a ction, which affects the cardiac action 
potential. The significance of the me mbrane action  in the tr eatment of arrhyth mias is  uncertain.  
 

SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
73 Propranolol hydrochloride extended -release capsules  should not be considered a simple mg- for- 
mg s
ubstitu te for conventional propranolol and  the blood lev els ach ieved  do not m atch (are lower 
than) those of two  to four tim es daily dosing with the sam e dose (see  DO
SAG E AND 
ADMINIS TRATION ). When changing to propranolol hydroch loride extended -release capsules  
from  conventional propranolol, a possible need for retitration  upwards should be considered, 
especially to  maintain e ffectiveness at the end of the dosing interval. In m ost clinical settings, 
however, such as hypertension or angina  where there is  little  correlation between plas ma levels 
and clinica l effect , propranolol hydrochloride extended- release capsules have been 
therapeutically equivalent to  the same mg dose of conventional propranolol hydrochlori de 
extended -release capsul es as assesse d by 24- hour effect s on blood pressure and on 24 -hour 
exercise responses of heart  rate,  systolic pressure, and rate pressure product. 
 
 
Mechanism of Action  
The m echanism  of the antihypertensive effect of  propranolol has  not been  established.  Among 
the factors that may be involved in contribu ting to the antihypertensive action  include: 
(1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of 
tonic sy mpathetic  nerve outflow from  vaso motor centers  in the brain. Although total peripheral 
resistance may  increase initially,  it readjusts to  or below the pretreat ment level  with  chronic use 
of propranolol. Effects of propranolol on plasm a volu me appear to be minor and somewhat 
variable.  
 In angina pectoris, propranolol generally  reduces  the oxygen  requ irement of the heart  at any 
given  level  of effort  by blocking the catecholamine- induced increas es in the heart  rate,  systolic 
blood pressure, and the velocity and extent of my ocardial contraction. Propranolol m ay increase 
oxygen  requirem ents by increasing  left ventricular fiber length, end di astolic  pressure,  and 
systolic  ejection  period. The  net physiologic effec t of beta- adrenergic blockade is usually 
advantageous and is m anifested during exercise by delaye d onset of pai n and increased work 
capacity.  
 Pr
opranolo l exerts  its antiarrh ythmic effects  in concentratio ns associated  with  beta-adrener gic 
blockade, and this appears to be its principal antiarrhythm ic mechanism  of action. In dosages 
greater  than  required  for beta blockade, propranolo l also exert s a quinidine- like or anesthetic -like 
membrane action  which  affects  the cardiac acti on potential.  The significance  of the me mbrane 
action in the treatment of arrhyth mias is uncertain. 
 The m echanism  of the anti -migraine effect  of propranolol has not been established. Beta-
adrenergic recep tors have been  demons trated in the p ial vessels of t he brain.  
  
PHARMACOKINETICS AND DRUG ME TABOLISM  
Absorption  
Propranolol is  highly lipophilic and  almost  completely  absor bed after oral ad ministration. 
However, it undergoes high first pass m etabolism by the liver  and on average,  only about 25% of 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
74 propranolo l reaches  the syste mic circulat ion. Propranolo l hydrochloride extended -release 
capsules (60, 80, 120, and 160 mg) release propranolol HCl  at a controlled and predictable rate. 
Peak  blood levels  follo wing dosing with  propranolol hydrochloride extended- release capsules 
occur at about 6 hours. 
 The effect of food on propranolo l hydrochloride extended- release capsules bioavaila bility has not 
been investigated.   
Distribution  
Approxim ately 90% of circulat ing propranolol is bound to pla sma proteins (albumin and alpha-1-
acid glycoprotein). The bin ding is e nantio mer-selecti ve. The S( –)-enantio mer is preferentially 
bound to alpha-1-glycoprotein and the R(+) -enantio mer preferentially bound to albumin. The 
volume of distribution of propranolol is  approximately 4 liters/kg.  
 
Propranolol crosses  the blood- brain  barrier  and the placenta, and is distributed i nto breast m ilk. 
  
Metabolism  and Elimination 
Propranolo l is extensiv ely metaboli zed with most  metabolites appear ing in the ur ine. Propranolo l 
is metabolized  through three  primary routes: aromatic hydroxylation ( mainly  4-hydroxylation), 
N-dealkylation followed by further side-chain oxidation, and  direct  glucu ronidation. It has been 
estimated t hat the p ercentage co ntributions of these routes to  total m etabolism  are 42%, 41% and 
17%, respectively, but with considerable variab ility between  individuals.  The four m ajor 
metabolites  are pro pranolol gl ucuronide, naphthyl oxylactic  acid  and gluc uronic acid, and sulfate 
conjugates of 4- hydroxy propranolol. 
 
In-vitr
o studies have indicated  that th e aro matic hydroxylation of propranolol is  catalyzed  mainly 
by polymorphic CYP2D6. Side-chain oxidation is m ediated mainly by CYP1A2 and to som e 
extent by CYP2D6. 4-hydroxy propranolol is  a weak  inhibitor of CYP2D6.  
 
Propranolol is  also a substrate of CYP2C19 and a substrate for the inte stinal efflux tr ansporte r, p-
glycoprotein (p-gp). Studies suggest however  that p-gp is not dose- limiting for intestinal 
absorption of propranolol in the usual therapeutic dose range.  
 
In healthy subjects, no difference was observed between CYP2D6 extensive m etabolizers (E Ms) 
and poor me tabolizers  (PMs) with  respect  to oral clearance or eli mination  half-life. Partial 
clearance of 4- hydrox y propranolo l was  significantly  higher and naphthyloxyactic acid was 
signi ficantly lower in E Ms than PM s. 
 When m easured at steady state over a 24 -hour period the areas under the propranolol plasma 
concentration -time curve (AUCs) for the propra nolol hydrochloride extended- release capsules 
are approxi mately 60% to 65% of the AUCs for a comparable divided daily dose of propranolol 
hydrochloride extended -release ca psules.  The lower  AUCs  for the propranolol hydrochloride 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
75 extended- release capsules are due to greater  hepatic m etabolism of propranolol, resulting from 
the slower  rate of absorption of propranolol. Over a twenty -four (24) hour period, blood levels 
are fairly constant for about t welve (12) hours, then  decline exponentially. The apparent plasm a 
half-life is about 10 hours. 
 
 
Enantiomers  
Pr
opranolol is  a racem ic mixture  of two enanti omers, R(+) and S( –). The S(–)- enantio mer is 
approximately 100 tim es as poten t as the R(+) -enantio mer in blocking beta adrenergic receptors. 
In norm al subjects recei ving oral dos es of racemic propranolol, S(–)- enantio mer concentrations 
exceeded t hose of the R(+) -enanti omer by 40 -90% as a res ult of stereoselective hepatic 
metabolis m. Clearance of the phar macologically  activ e S(–)-propranolol is  lower  than R(+) - 
pr
opranolol after  intravenous and oral doses. 
 
 
Sp
ecial Po pulation 
Geriatric  
The pharma cokinetics of  propranolol hydrochloride extended -release capsules have not been 
investigate d in patient s ove r 65 year s of age.  
 
In a study of 12 elderly (62-79 years old) and 12 young  (25-33 years  old) healthy  subjects,  the 
clearance of  S-enantio mer of propranolol was dec reased  in the elder ly. Additio nally, the hal f-life 
of both the R- and  S-propranolol were prolonged in the elderly com pared with the young 
(11 hours vs. 5 hours).  Clearance of propranolol is  reduced  with  aging due to declin e in oxidation capacit y (ring 
oxidation and  side chain  oxidation). Conjugation capacity  remains unchanged. In a study of 32 
patients  age 30 to  84 years  given  a single  20-mg dose of propranolol, an inverse correlation was 
found between age and the partial m etabolic  clearances to 4- hydroxyp ropranolol (40H P ring 
oxidation) and to naphthoxylactic acid (NLA- side chai n oxidation). No correlatio n wa s found 
between age and the partial m etabolic clearance to propranolol glucuronide (PPLG  conjugation). 
 Gen
der 
In a study of 9 healthy women and 12 healthy men, neither the administration of testosterone nor the regular  course of the m enstrual cycle affected the plas ma binding of the propranolol 
enantio mers. In contrast,  there was  a significant,  although non -enantiosele ctive di minution of the 
binding of propranolol after treatme nt with ethiny l estradi ol. These finding s are i nconsistent with 
another study,  in which  administration  of testost erone cypionate confirm ed the sti mulatory role 
of this hormone on propranolol m etabolism and concluded that the clear ance of propranolol in 
men is dependent on circulating  concentrations of testosterone. In women, none of the m etabolic 
clearances for propranolol showed any significant associatio n with either estra diol or 
testosterone.  
  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
76 Race  
A study conducted in 12 Caucasian and 13 African-Am erican  male subjects  taking propranolol, 
showed that  at steady  state,  the clearance of R(+) - and S(–)-propranolol were about 76% and 
53% higher in  African -Americans  than  in Caucasians,  respectively.  
 
Chinese subjects  had a greater  proportion (18% to  45% higher) of unbound propranolol in 
plasma compared to Caucasians, which was ass ociated with a lower pla sma concentration of 
alpha -1-acid glycoprotein. 
 Renal Insufficie ncy 
The pharmacokinetics of propranolol hydrochloride extended- release capsules have not been 
investigated  in patients  with renal insufficiency.  
 In a study conducted in  5 patients  with  chronic renal failure, 6 patients on regular dialysis, and 5 
healthy  subjects,  who  received  a single oral dose of 40 m g of propranolol, the peak plasm a 
concentrati ons (C max) of propranolol in the chronic renal failure group were 2 to 3-fold higher 
(161±41 ng/mL) than those observed in the dialysis patients (47±9 ng/mL) and in the healthy subjects (26±1 ng/mL). Propranolo l plas ma clearance was  also re duced  in the patients  with 
chronic renal  failure.  Studies have reported a delayed absorption rate and a reduced  half-life of 
propranolol in  patients with ren al failure of varying seve rity. Despite this shorter plas ma half -
life, propranolol peak plasm a levels were 3 -4 times higher and total plasm a levels of m etabolites 
were up to 3 tim es higher  in these patients  than in subjects with norm al renal function.  
 Chronic ren al fail ure has been associated  with a decrease in  drug m etabolism via down 
regulation of hepatic cytochrome P450 activ ity resulting in a  lower “f irst-pass” c learance.  
Propranolo l is no
 t significantly dialyzable. Hepatic Ins ufficiency  
The pharmacokinetics of propranolol hydrochloride extended -release cap sules have not been 
investigated  in patients  with hepatic insufficiency. 
 Propranolol is extensively m etabolized by the l iver. In a study conducted  in 6 patients  with 
cirrhosis  and 7 healthy  subjects  receiving  160 mg of a long-acting preparation of propranolol 
once a day for 7 days, the steady -state propranolol concentration in patients with cirrhosis was 
increased  2.5-fold in comparison to  controls. In the  patients  with  cirrho sis, the half- life obtained 
after a single intravenous dose of 10 mg propranolol increased to 7.2 hours com pared to  
2.9 hours in  control (see PRECAUTIONS ). 
 
Drug Interactions  
All drug interaction studies w ere conducted  with  propranolol. Ther e are no data on drug 
interactions  with  propranolol hydrochloride extended- release capsules  capsules.  
 
Interactions with  Substrates,  Inhibitors or Inducers of Cytochrom e P-450 Enzym es 
Because pr opranolo l’s m etabolism involves multiple pathwa ys in the Cytochro me P-450 system 
(CYP2D6, 1A2, 2C19), co- administration with d rugs that are m etabolized  by, or affect  the 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
77 activity  (induction or inhibition) of one or more of these pathways m ay lead to clinically r elevan t 
drug interactions (see Drug Interactions under P RECAUT IONS ). 
 
Substrates or Inhibitors of CYP2D6  
Blood levels  and/or toxicity of propranolol m ay be increas ed by co-administration  with 
substrates or inhibitors of CYP2D6, such as amiodarone, cimetidine, delavudin, fluoxetine, 
paroxetine,  quinidine, and  ritonavir. No interactions were observed  with  either ranitidine  or 
lansoprazole.  
Substrates or Inhibitors of CYP1A2  
Blood levels  and/or toxicity of propranolol m ay be increas ed by co-administration  with 
substrates or inhibitors of CYP1A2, such as im ipramine, cimetidine, ciprofloxacin, fluvoxamine, 
isoniazid, ritonavir, theo phyllin e, zileuton, zolm itriptan, and rizatriptan.  
 
Substrates or Inhibitors of CYP2C19 
Blood levels  and/or toxicity of propranolol m ay be increas ed by co-administration  with 
substrates  or inhibitors of CYP2C19, such as fluconazole, cimetidine, fluoxetine, fluvoxamine, 
tenioposide, and  tolbutam ide. No interaction was observed with om eprazole.  
 
Inducers  of Hepatic Drug  Metabolism  
Blood levels of propranolol m ay be decreased  by co-administration  with  inducers  such  as 
rifampin, ethanol, phenytoin, and phenobarbital. Cigarette smoking also induces hepatic 
metabolism and has been shown to increase up to 77% the clearance of propranolol, resulting in 
decreased plas ma concentrations.  
 
Cardi ovascular Drugs  
Antiarrhythm ics 
The AUC of propafenone is increased by m ore than 200% by  co-administration  of propranolol. 
 The metabolism of propranolol is  reduced  by co-administration of quinidine, leading to a two to 
three fold  increas ed blood concentration  and greater de grees of clinical beta-block ade. 
 The m etabolism of lidocaine is inhib ited by c o-adm inistration of propranolol, resulting in a 25% 
increase in  lidocaine co ncentratio ns. 
 
Calcium Channel Blockers  
The mean C max and AUC of propranolol are increased respectively,  by 50% and  30% by  
co-administration of nisoldipine and  by 80% and  47%,  by co-administration of nicardipine. 
 The mean C max and AUC of nifedipine are increased  by 64% and 79%, respectively,  by co -
administration of propranolol. 
 Propranolol does not affect  the phar macokinetics of verapamil and norverapam il. Verapamil does 
not affect the pharmacokinetics of propranolol. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
78 Non-Cardiovascular  Drugs  
Migraine Drugs  
Administration of zolmit riptan or rizatriptan wit h propranolol re sulted  in increa sed 
concentrati ons of zolm itriptan  (AUC increased  by 56% and C max by 37%) or rizatriptan (the 
AUC and Cmax were increased  by 67% and 75%, respectively).  
 
Theophylline  
Co-administration of theophylline with propra nolol decreases  theophylline oral  clearance by 30% 
to 52%. 
 
Benzodiazepines  
Propranolo l can  inhib it the  metaboli sm of diazepam, resultin g in in creased concentrations of 
diazepam  and its m etabolites. Diazep am does not alter the ph armacokinetics of propranolol. 
 The pharm acokinetics of oxazepam , triazola m, lorazepam , and alprazolam are not affected by 
co-administration of propranolol. 
 
Neuroleptic Drugs  
Co-administration of long-acting propranolol at doses greater  than  or equal  to 160 m g/day 
resulted  in increased  thioridazine plas ma concentrations ranging from  55% to 369% and 
increased  thioridazine metabolite  (mesoridazine)  concentrations ranging from  33% to  209%. 
 Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol 
plasma level.  
 
Anti-Ulcer  Drugs  
Co-administration of propranolol with cim etidine, a non -specifi c CYP45 0 inhibitor, increased 
propranolol AUC an d Cmax by 46% and  35%, respectively.  Co-administration  with a luminum 
hydroxide gel (1200 mg ) may result in a d ecrease in propranolol concentrations. 
 Co-administration of  metoclo pramide with the lo ng-acting propranolol did not have a significant 
effect on propranolol’s pharm acokinetics.  
 
Lipid Lowering Drugs  
Co-administration of cholestyra mine or colestipol with propranolol resulted in up to 50% 
decrease in  propranolol concentrati ons. 
 Co-administration of propranolol with lovastatin  or pravastatin,  decreased 18% to 23 % the AUC 
of both, but did  not alter  their  pharmacodynam ics. Propranolol did not have an effect on the 
pharm acokinetics of fluvastatin.  
 
Warfa rin 
Concom itant ad ministration  of propranolol and  warfarin  has been  shown to  increase warfarin 
bioavailability and increase prothrombin tim e. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
79  
 
PHARMACODYNAMICS AND CLINICAL EFFECTS  
Hyperten sion 
In a retrospective, uncontrolled study, 107 patients with diastolic blood pressure 
110 to 150 mmHg received propranolol 120 m g t.i.d. for at least 6 months, in addition to 
diuretics  and potassium, but with  no other hypertensive agent.  Prop ranolol contributed to control 
of diastolic  blood pressure,  but the magnitude of the effect of  propranolol on blood pressure 
cannot be ascertained.  
 Four double-blind, random ized,  crossover studies were conducted in a total of 74 patients  with 
mild or moderately severe hypertension treated  with propranolol hydrochl oride extended -release 
capsules 160 mg once daily or propranolol 160 mg given either once daily or in two 80 m g 
doses. Three of these studies were conducted over a 4- week  treat ment period. One  study was 
assessed  after  a 24-hour period. Propranolol hydrochloride extended -release capsules were as 
effective as  propranolol in  controlling hypertensio n (puls e rate, systolic  and diastolic  blood 
pressure) in  each  of these trials.  
 
Angina Pectoris  
In a double- blind , placebo -controlled study of 32 patients  of both sexes,  aged  32 to  69 years,  
with stable  angina,  propranolol 100 mg  t.i.d. was  administered for 4 weeks and shown to be m ore 
effective than  placebo  in reducing  the rate of angina episodes and in prolonging total exercise 
time. 
 
Twelve mal e patients with m oderately severe angin a pectoris wer e studied in a double-blind, 
crossover study. Patients were random ized to either Propranolol hydrochloride extended- release 
capsules 160 mg daily or conventional propranolol 40 m g four ti mes a day for 2 weeks. 
 Nitr
oglycerine tablets w ere all owed during the study.  Blood pressure,  heart  rate and  ECG 's were 
recor ded during serial  exerci se treadm ill testing. Propranolol hydrochloride extended- release 
capsules were as effective as conventional pro pranolol for exercise hear t rate, systoli c and 
diastolic  blood pressure,  durat ion of anginal pai n and ST-segment depression before  or after 
exercise, exercise duration, angina attack  rate and  nitroglycerine consumption. 
 In another double-blind, randomi zed, crossover trial,  the effectiveness of propranolol 
hydrochloride extended -release ca psules 160 mg daily and conventional propranolol 40 m g four 
times a day were evaluated in 13 patients with  angina. ECG' s were recorded whil e patients 
exercised u ntil angina d eveloped. Propranolo l hydrochlor ide ex tended -release caps ules were as 
effective as  conventional propranolol for amount of exercise perfor med, ST- segment depression, 
number of anginal attacks, amount of nitrogl ycerine  consum ed, systolic  and diastolic  blood 
pressures  and heart  rate at  rest and after exercise.  
 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
80 Migraine 
In a 34- week, placeb o-controlled, 4-period, dose-finding cro ssover study  with a doub le-blind 
random ized treat ment sequence,  62 patients  with  migraine received propranolol 20 to 80 mg 3 or 
4 tim es daily. The headache unit index, a co mposite  of the number  of days with headache and the 
associated  severity  of the headache,  was significantl y reduced fo r patien ts receiving propranolol 
as compared  to those on placebo.  
 
Hypertrop hic Subaortic Stenosis  
In an uncontrolled series  of 13 patients  with New York  Heart  Associa tion (NYHA)  class  2 or 3 
sympto ms and hypertrophic subaortic stenosis diagnosed at  cardiac ca theterization,  oral 
propranolol 40-80 mg t.i.d. was  administered  and patients  were followed  for up to  17 months. 
Propranolol was  associated  with  improved NYHA clas s for mos t patients.  
 INDICAT IONS AND USAGE  
Hyperten sion 
Propranolol hydrochloride extended -release capsules  are indicated in the management of 
hypertension. It may be used alone or used in combination with other antihypertensive agents, 
particularly  a thiazide  diure tic. Propranolol hydrochloride ex tended -release capsules is not 
indicated  in the m anage ment of hypertensive em ergencies.  
 Angina Pectoris Due to  Coronary Atherosclerosis  
Propranolol hydrochloride extended -release capsules  are indicated  to decrease angina frequency 
and increase exercise to lerance in  patients with angina pectoris.  
 Migraine 
Propranolol hydrochloride extended -release capsules are indicated for the prophylaxis of 
common mi graine headache. The efficacy of pro pranolo l in th e treatment of a m igraine attack 
that has started has not been established, and propranolol is  not indicated  for such  use. 
 
Hy
pertrop hic Subaortic Stenosis  
Propranolol hydrochloride extended -release capsules i mprove NYHA functional class in 
symptom atic patients with hypertrophic subaortic stenosis.  
 
CONTRAINDICATIONS  
Propranolol is  contraindicated  in 1) cardiogeni c shock ; 2) sinus bradycardia  and greater  than 
first-degree  block; 3) bronchial asthm a; and 4) in  patients  with  known hypersensitivity  to 
propranolol hydrochloride.  
WARNI NGS  
Angina Pectoris  
There have been reports of exacerbation of  angina and, in  some cases,  myocardi al infarction, 
follo wing abrupt discontinuance of propranolol therapy.  Therefore,  when discontinuance of 
propranolol is planned, the dosage should be gradually reduced over at least a few  weeks, and the 
patient should be cautioned against interruption or cessation of therapy without the physician's 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
81 advice.  If propranolol th erapy is interrupted and exacerbati on of angina occurs, it us ually is 
advisable to reinstitute pr opranolol th erapy and take o ther measures  appropriate for the 
management  of unstable angina pectoris. Since coronary artery dise ase may be unrecogni zed, it 
may be prudent to follow the above advice in  patients  considered  at risk of having occult 
atherosclerotic  heart disease  who are given propranolol for other indications.  
 
Hypersensitivity and S kin Reactions  
Hypersensitivity reactio ns, including anaphylactic/anaphylact oid reactio ns, have been associated 
with the a dministration of  propranolol (see ADVERS E RE ACTIONS ). 
 
Cutaneous reactions, including Stev ens-Johnson Syndro me, toxic epi dermal necrolysis, 
exfoliative d ermatitis, er ythema multiforme, and urticar ia, have been rep orted with u se of 
propranolol (see ADVERS E REACTION S). 
 
Cardiac Failure 
Sympathetic stimulation m ay be a vital co mponen t supporting circulato ry functio n in patients 
with congestive heart failure, and its inhibition by beta blockade m ay precipitate  more  severe 
failure. Although beta blockers should be avoided in overt congestiv e hear t failure , some have 
been  shown to  be highly beneficial  when  used with close follow-up in patients wit h a history of 
failure  who  are well  compensated  and are r eceiving  diuretics  as needed.  Beta -adrenergic 
blocking agents  do not abolish the inotropic action of digitalis on heart m uscle.  
 
In
 Patients without a History of H eart Failu re, continued use of beta blockers can, in som e cases, 
lead to cardiac failure.  
 
Nonallergic Bronchospasm (e.g., Chronic Bronchitis, Emphysema) 
In general,  patients  with  bronchospastic lung disease should not receive beta-blockers. 
Propranolo l shoul d be ad ministered  with  caution  in this setting since it m ay provoke a bronchial 
asthmatic attack by blocking bronchodila tion produce d by endogenous an d exogenous 
catech olamine stimulation of beta- receptors.  
 
Major Sur gery 
Chronical ly adminis tered be ta-blocking  therapy  should not be ro utinely  withdrawn prior to  major 
surgery, however  the imp aired ability of the heart  to respon d to refle x adrenergi c stimul i may 
augment th e risk s of genera l anest hesia and surgi cal procedures. 
 
Diabetes a nd Hypoglycemia 
Beta-adrenergic blockad e may prevent the appearance of certain premonitory signs and 
symptom s (pulse rate and pressure changes) of  acute hypoglyce mia, especially  in labile  insulin - 
dependent diabetics.  In these patients,  it may be more  difficult to  adjust the dosage of insulin. 
 
Propranolol therapy,  particularly whe n give n to infant s and child ren, diabetic or not, has been 
associated w ith hypoglyce mia especially dur ing fasting  as in preparation  for surgery. 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
82 Hypoglyce mia has been reported in patients tak ing propranolol after prolonged physical exertion 
and in patients with ren al insu fficiency.  
 
Thyrotoxicosis 
Beta-adrenergic blockade m ay m ask certain clinical signs of hyp erthyroidis m. Therefore, abrupt 
withdrawal  of propranolol m ay be followed by an exacer bation of sympto ms of hyp erthyr oidism, 
including thyroid storm. Propranolol m ay change thyroid -function tests,  increasing  T4 and 
rever se T3, and decreasin g T3. 
 
Wolff-Parkinson- White Syndrome  
Beta-adrenergic blockade in p atients wit h Wolff-Parkinson -White syndrom e and tachycardia has 
been associated with severe bradycardia requiri ng treat ment with a pacemaker. In one case, this 
result  was reported  after  an initial dose of 5 m g propranolol. 
 PRECAUTIONS  
General  
Propranolol should be used  with caution in patients with im paired hepatic or renal  function. 
Propranolol hydrochloride extended- releas e capsule s are not indicated for the treat ment of 
hypertensive em ergencies.  
 
Beta-adrenergic recep tor blockade can cause red uction of intraocular pressure. Patients should be 
told that propranolol hydrochloride extended-re lease caps ules may interfere with the glauco ma 
screening test. W ithdrawal m ay lead to a r eturn of increased  intraocular pressure.  
 While taking beta -blockers, patien ts with  a history of severe anaphylacti c reactio n to a variet y of 
allergens m ay be more reactive to repeated  challenge, eithe r accidental , diagnostic , or 
therapeutic.  Such  patients  may be unresponsive to the usual doses of epinephrine used to treat 
allergic  reaction.  
 
Clinical L aboratory Tests 
In p
atients  with  hypertension, use of propranolol ha s been associa ted with elevated levels of 
serum  potassium, serum transam inases, and alkal ine phosphatase. In severe heart failure, the use 
of propranolol has  been  associated  with increase s in Bloo d Ure a Nitrogen. 
 Drug Interactions  
Ca
ution shoul d be exercise d whe n propranolol hydrochloride extend ed-release cap sules are 
administered with drugs that have an affect  on CYP2D6, 1A2, or 2C19 metabolic pathways. Co - 
admini
stration of such drugs with propranolol may lead  to clinic ally relevant drug interactions 
and changes on its efficacy and/or toxicity  (see D
rug Interactions in  PHARMACO KINETICS  
AND DRUG META BOLISM). Alcohol when used concomitantly with propranolol, m ay 
increase plas ma levels of propranolol. 
   
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
83 Cardiovascular Drugs 
Antiarrh ythmics 
Propafenone has negative inotropic and beta-blocking properties that  can be additive to those of 
propranolol. 
 Quinidine in creas es the concentr ation of propranolol an d produce s greater  degrees  of clinical 
beta-blockade and may cause postural hypotension.  Amiodarone is an antiarrhythm ic agent with  negative chronotropic properties that  may be 
additive to  those seen  with β -blockers such as propranolol. 
 The clearance of lidocaine is r educed wit h administratio n of propranolol . Lidocaine toxicit y has 
been reported following co- administration with propranolol. 
 Caution should be exercised when administering propranolol hydrochloride extended- release 
capsules  with  drugs that  slow A-V nodal conduction, e.g., lidocaine and  calcium  channel 
blockers.  
Digita lis Glycosides  
 Both  digitalis  glycosides  and beta-blockers slow atrioventricular conductio n and decrease heart 
rate. Concom itant use can  increase the risk  of bradycardia.  
 
Calcium  Channel Block ers 
Caution sho uld be exercised when p atients receiving a beta- blocker  are administered  a calciu m- 
channel -blocking drug  with  negative inotropic and/or chronotropic effects. Both agents m ay 
depress m yocardial contractility  or atrioventricula r conduction. 
 There have been  reports  of sign ificant bradycardia, heart failu re, and cardiovascu lar colla pse 
with concurrent use of verapamil and beta-blockers. 
 
Co-administration of propranolo l and  diltiazem in patie nts with cardiac dis ease has been 
associated with bradycardia, hypotension, high degree  heart  block, and  heart  failure.  
 
ACE Inhibitors  
When  combined  with  beta -blockers, ACE  inhibitors can cause hypotension, particularly in the 
setting  of acute m yocardial  infarction. 
 
The antihypertensive effects of  clonidine may be antagonized by beta -blockers. Propranolol 
hydrochloride extended- release capsules should be ad ministered cautiously to patients 
withdrawing from  clonidine. 
 
Alpha Blockers  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
84 Prazosi n has been associate d wit h prolongation of first dose hypotens ion in the presence of beta-
blocker s. 
 
Postural hypotension has been reported in patients taking both beta -blockers and terazosin or 
doxazosin.  
Reserpine  
Patie nts receiving catecholamine-depleting drugs, such as reserpine should be closely observed 
for excessive reduction of resting  sympathetic  nervous activity,  which  may result  in hypotension, 
marked bradycardia, vertigo, syncopal attacks,  or orthos tatic hypotension. 
 
Inotrop ic Agents  
Patients on long- term therapy with propranolol m ay experience uncontrolled hypertension if 
administered epinephrine as a consequence of unopposed alpha-receptor stimulation. 
Epinephrine is  therefore not indicated  in the treat ment of pro pranolol overdose (see 
OVERDOSAG E). 
 
Isoproterenol and Dobutamine 
Propranolo l is a co mpetitive in hibitor of beta-receptor agonists, and  its effects can be reversed  by 
administration of such agents, e.g., dobutamine or isoproterenol. Also, propranolol ma y reduce 
sensitivity to dobutam ine stress echocardiogr aphy in patients  undergoing evaluation  for 
myocardial  ischem ia. 
 
Non-Cardiovascular Drugs  
Nonsteroida l Anti- Inflammatory Drugs  
Nonsteroidal anti- inflamm atory drugs (NS AIDs) have been  reported  to blunt the antihyperte nsive 
effect of beta- adren orece ptor blocking agen ts. 
 
Administration of indomethacin with  propranolol m ay reduce the efficacy  of propranolol in 
reducing  blood pressure  and heart  rate.  
 
Antidepre ssants  
The hypotensive effects  of MAO inhibitors or tricyclic  antidepressants may be exacerbated when 
administer ed with  beta-blockers by  interf ering  with the beta blocking activit y of propranolol. 
 
Anesthetic  Agents  
Methoxyflurane and trichloroethylene m ay depress  myocardial contractility when ad ministered 
with propranolol.  
Warfarin 
Propranolol when  administered  with  warfarin  increases  the concentration  of warfarin. 
Prothro mbin tim e, therefore,  should be monitored. 
 
Neuroleptic Drugs  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
85 Hypotension and  cardiac arrest  have been reported with the conco mitant use of propranolol and 
haloperidol. 
 
Thyroxine 
Thyroxine m ay result  in a lower  than  expected  T3 concentration when used concom itantly with 
propranolol.  
Carcinogenesis, Muta genesis, I mpairment  of Fertility  
In dietary  administration  studi es in which  mice and  rats were treated  with  propranolol 
hydrochloride for up to 18 months at doses of up to  150 m g/kg/day,  there was  no evidence of 
drug- related  tumorigenesis. On a bo dy surface area basis, this dose in th e mouse and rat is, 
respectively , about equal to and  about twice  the m aximum r ecommended  hum an oral daily  dose 
(MRHD) of 640 mg propranolol hydrochloride. In a study in which both m ale and fema le rats 
were exposed to propranolol hydrochloride in their diets  at concentratio ns of up to 0.05% (about 
50 mg/kg body weight and less than the MRHD), from 60 da ys prior to  mating  and throughout 
pregnancy and  lactation  for two  generations, ther e were no effects on fertility. Based on differing 
results from  Ames Tests perfor med by different  laborato ries, there is  equivocal  eviden ce for a 
genotoxic effect  of propranolol in  bacteria ( S. typhimurium strain TA 1538). 
 Pregnancy: Pregnancy Category C  
In a series of reproductive and develop mental tox icology studies, propranolol was given to rats 
by gavage or in the diet throughout pregnancy and lactation. At doses of 150 mg/kg/day, but not 
at doses of 80 mg /kg/day  (equivalent to the MRHD on a body surface ar ea basis),  treat ment was 
associated w ith embryotoxicity (re duced litter  size and increased  resorption rates)  as well  as 
neonatal toxicit y (deaths) . Propranolol hydrochlor ide also was administered  (in the feed)  to 
rabbits (throughout pregnancy and lactation) at doses as high  as 150 mg/kg/day (about 5 tim es 
the m aximum recomm ended human oral daily dose). No evidence of embryo  or neonatal  toxicity 
was noted.  Th
ere are no adequate and well -controlled  studie s in pregnan t women. Intrauterine growth 
retardation,  small placen tas, and congenital  abnormalities  have been  reported in neonates whose 
mother s received propranolol during pregn ancy.  Neonates  whose mothers are  receiving 
propranolo l at parturition have exhi bited bradycardia, hypo glycemia and/or res piratory 
depression. Adequate facilities  for monitoring such infants at birth should be available. 
Propranolol hydrochloride extended -release capsules  should be used durin g pregnancy only if the 
poten tial benef it justifies the potentia l risk to the f etus. 
 
Nursing Mothers  
Propranolo l is excrete d in hum an milk. Caution should be exercised when  propranolol 
hydrochloride extended- release capsules  are ad ministered  to a nursing wo man. 
 Pediatric Use  
Safety  and effectiveness  of propranolol in  pediatric patients have not been  established.  
 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
86 Bronchospasm and congestive heart  failure  have been  reported  coincident with  the 
administration of propranolol th erapy in pediatric patients.  
 
Geri atric Use  
Clinical studies of propranolol hydrochloride extended- releas e cap sules did not include sufficient 
numbers of subjects aged 65 and over to determine whether  they respond differently  from 
younger  subjects.  Other  reported  clinical experience has  not identif ied differences  in responses 
between  the elderly  and younger  patients.  In gener al, dose selection  for an  elderly  patient  should 
be cautious, usually starting  at the low end of the dosing range, reflecting  the greater  frequency  
of the decreased hepatic, renal or cardiac fun ction, and of concomitant disease or other drug 
therapy.  
 
ADVERS E REACTIONS  
The following adverse events  were o bserved and  have been  reported  in patients  using 
propranolol. 
 Cardiovascular: Brad ycardia;  congestive heart  failure; intensificatio n of AV block; 
hypotension; paresthesia of hands; thrombocytopenic purpura; arterial  insufficiency, usually of 
the Raynaud type.  
 Central Nervous System:  Light -headedness; mental depression manifested by insomnia, 
lassitude, w eakness, fatigue; catatonia; visual  disturbances; hallucinations; vivid dream s; an acute 
reversible syndrome characterized  by disorientation for time and place, short- term memory loss,  
emotional lability,  slightly  clouded sensorium, and decreased perform ance on 
neuropsychom etrics.  For immediate release form ulations, fatigue, leth argy,  and vivid dream s 
appear  dose related.  
 Gastr ointestinal:  Nausea, vo miting, epigastric distr ess, abdom inal cramping, diarrhea, 
constip ation, mesenter ic art erial thrombosis, ischem ic colitis.  
 Al
lergic: H ypersensitivity reactions , includin g anaphylactic/anaphylactoid  reactions;  pharyngitis 
and agranulocytosis; erythem atous rash; fever combined with  aching and  sore throat; 
laryngospas m; respiratory distress.  
 Respiratory:  Bronchospasm. 
 Hemat ologic: Agranulocytosis, nonthrombocytopenic purpura, an d thrombocytopenic purpura. 
 Autoimm une: Syste mic lupus erythem atosus (SLE).  
 Skin and mucou s membranes : Stevens -Johnson Syndrom e, toxic epider mal necrolysis, dry 
eyes, ex foliative d ermatitis, er ythema multifor me, urtica ria, alopecia, SL E-like rea ctions, and 
psoriasisiform rashes. Oculomucocutaneous syndrome involving the skin, serous m embranes, 
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
87 and conjunctivae reported  for a be ta-blocker (practolo l) have not been asso ciated with 
propranolol. 
 Genitourinary : Male impotence; Peyronie' s disease.  
 
OVERDOSAGE  
Propranolol is  not significantly  dialyzable.  In the event  of overdosage or exaggerated  response, 
the following measures should be employed: 
 General : If ingestio n is or m ay have been recent,  evacuate gas tric contents, taking care to 
prevent pulmonary aspiration.  Supportive Therapy:  Hypotension and  bradycardia have been reporte d followin g propranolol 
overdose and  should be treated  appropriately. Glucago n can exert  potent inotropic and  
chronotropic effects and m ay be particularly usef ul for the treat ment of hypotension or depressed 
myocardial function after a propranolol overdose. Glucagon should be adm inistered as  
50-150 mcg/kg intravenously followed by continuous drip of 1-5 mg/hour for positive chronotropic effect . Isoproterenol, dopamine or phosphodiesterase inhibitors may also be useful. 
Epinephrine, however, may provoke uncontrolled hypertension. Bradycardia can be treated with atropin e or isoproterenol. Serious bradycardia ma y require temporary cardiac pacing.  
 
The electrocardiogram, pulse,  blood pressure,  neurobehavioral status an d intak e and output 
balance must be monitored. Isoproterenol and aminophylline m ay be used  for bronchospasm. 
 
DOSAG E AND ADM INISTRA TION 
General  
Propranolol hydrochloride extended -release capsules  provide propranolol hydrochloride in a 
sustai ned-release ca psule for ad ministration  once da ily. If patients  are swi tched from propranolol 
hydrochloride tablets  to propranolol hydrochloride extended- release capsules,  care should be 
taken  to assure  that the desired  therapeutic effect is maintained. Propranolol hydrochloride 
extended- release ca psules should not be con sidered a si mple mg -for-m g substit ute for 
propranolol hydrochloride tablets. Propranolol hydrochloride e xtended -release capsules  have 
different  kinetics and produces  lower  blood level s. Retitration  may be necessary,  especially  to 
maintain effectiveness at the end of the 24-hour dosing interval. 
 
Hy
perten sion 
The usual initial dosage is 80 mg propranolol hydrochloride extended- releas e capsules once 
daily, whether used alone or added to  a diuretic.  The dosage may be increased to 120 m g once 
daily or higher until adequate blood pressure control is  achieved.  The usual m aintenance dosage 
is 120 to 160 mg once daily. In some instances a dosage of 640 m g may be required. The ti me 
needed for full hypertensive response to a given dosage is variable and may range from a few 
days to several weeks.  
   
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
88 Angina Pectoris  
Starting with 80 mg propranolol hydrochloride extended- release caps ules once daily,  dosage 
should be gradually  increased  at three- to  seven-day intervals until o ptimal respo nse is obtai ned. 
Although individual patients m ay respond at any  dosage level, the average optim al dosage 
appears  to be 160 mg once daily.  In angina  pectoris,  the value and  safety  of dosage exceeding 
320 mg per day have not been established. 
 If treatment is to be d iscontinued, reduce dosage gradually over a perio d of a fe w weeks (see 
“WARNINGS ”). 
 
Migraine 
The initial oral dose is 80 mg propranolol hydrochloride extended- release capsules once daily. 
The usual ef fective dose range  is 160 to  240 m g once daily. The dosage may be increased 
gradually to achieve opti mal mi graine prophylaxis. If a satisfactory response is not obtained 
within four to six weeks af ter reaching the maximal dose, propranolol hydrochloride extended- 
release capsules  therapy  should be discontinued. It  may be advisable to  withdraw the drug 
gradually over a period of several weeks dep ending on the patient 's age,  comorbidity, and  dose of 
propranolol hydrochloride extended -release capsules.  
 
Hypertrop hic Subaortic Stenosis  
The usual dosage is 80 to 160 mg propranolol hydrochloride extend ed-release ca psules once 
daily.  
 
HOW SUPPLIED  
Propranolol hydrochloride extended -release capsules  
 
Each  white  capsule,  identified  by 3 narrow  bands, 1 wid e band, an d “A K 60, ” contain s 60 mg of 
propranolol hydrochloride in  bottles of 100 (NDC 43478-900-88). 
 Ea
ch white/light blue capsule, identified by 3  narrow bands, 1 wide band, and “AK 80,” contains 
80 m g of p ropranolol hydrochloride in bottles of 100 (NDC  43478-901- 88). 
 Each  white/dark  blue capsule,  identified by 3 narrow bands, 1 wide band, and “AK 120,” 
contains 120 mg of propranolol hydrochloride in bottles of 100 (NDC 43478-902-88).  Each dark blue/light blue capsule,  identified  by 3 narrow  bands, 1 wide  band, and  “AK  160,” 
contains 160 mg of propranolol hydrochloride in bottles of 100 (NDC 43478-903-88).  
Store at 20° to 25°C (68° to 77°F); excursi ons permitted  to 15° to  30°C (59° to  86°F ). [See 
USP Controlled Room Temperature]  
 
Protect from light, moisture, freezing, and excessive heat.  
 Dispense in a tight, light -resistant container as defined in the USP.  
SOPPRANO Version 12.0  
Protocol # 14-067 -E 12 Feb 2018  
 ________________________________________________________________________________________________________  
 
 ____________________________________________________________________________________________   
  
89  
 
This product’s label may have been updated. For current package insert and further product 
information, please call our medical communications department toll- free at 1 -877-567-0862 
 
 
Manufactured for Rouses Point Pharmaceuticals, LLC 
Cranford, NJ 07016 
By Wyeth Pharmaceuticals, Inc.  
Philadelphia, PA 19101 
 
 
490F001 
Rev 12/10 
 
